document
intend
use
uk
event
world
health
organis
declar
influenza
pandem
start
depart
health
england
ukwid
lead
agenc
pandem
influenza
includ
devolv
administr
declar
uk
pandem
alert
level
case
pandem
influenza
identifi
within
uk
guidelin
relev
manag
patient
affect
seasonalinterpandem
influenza
lower
respiratori
tract
infect
communityacquir
pneumonia
exacerb
chronic
obstruct
pulmonari
diseas
copd
influenza
pandem
way
user
strongli
urg
ensur
refer
uptod
version
guidelin
webbas
access
point
synopsi
clinic
manag
adult
refer
hospit
sever
assess
hospit
patient
uncompl
influenza
infect
would
expect
make
full
recoveri
requir
hospit
care
uncompl
infect
ill
usual
resolv
seven
day
although
cough
malais
lassitud
may
persist
week
patient
worsen
preexist
comorbid
medic
condit
manag
accord
best
practic
condit
refer
publish
diseasespecif
guidelin
avail
exampl
nation
institut
clinic
excel
copd
guidelin
hospit
patient
influenzarel
pneumonia
score
see
box
high
risk
death
manag
sever
pneumonia
patient
bilater
lung
infiltr
chest
radiographi
consist
primari
viral
pneumonia
manag
sever
pneumonia
regardless
score
patient
score
increas
risk
death
consid
short
stay
inpati
treatment
hospit
supervis
outpati
treatment
decis
matter
clinic
judgment
patient
score
low
risk
death
treat
nonsever
pneumonia
may
suitabl
home
treatment
patient
primari
viral
pneumonia
score
consid
hduicu
transfer
gener
indic
hduicu
transfer
includ
persist
hypoxia
pao
kpa
despit
maxim
oxygen
administr
progress
hypercapnia
sever
acidosi
ph
septic
shock
patient
influenza
admit
intens
care
unit
manag
specialist
appropri
train
intens
care
respiratori
medicin
andor
infecti
diseas
pandem
flu
clinic
manag
patient
influenzalik
ill
influenza
pandem
gener
investig
follow
investig
recommend
patient
refer
hospit
appli
full
blood
count
patient
urea
electrolyt
patient
liver
function
test
patient
chest
xray
patient
puls
oximetri
patient
air
arteri
blood
gase
patient
cardiac
respiratori
complic
comorbid
ill
creactiv
protein
influenzarel
pneumonia
suspect
patient
subsequ
follow
hospit
outpati
clinic
gener
practition
repeat
chest
xray
obtain
around
six
week
respiratori
symptom
sign
persist
higher
risk
underli
malign
especi
smoker
year
age
investig
includ
ct
thorac
scan
bronchoscopi
consid
chest
xray
remain
abnorm
follow
microbiolog
investig
earli
pandem
uk
alert
level
virolog
patient
nose
throat
swab
viru
transport
medium
present
seven
day
onset
ill
acut
serum
ml
clot
blood
collect
convalesc
sampl
ml
clot
blood
obtain
interv
less
seven
day
bacteriolog
patient
influenzarel
pneumonia
blood
cultur
prefer
antibiot
treatment
commenc
pneumococc
urin
antigen
ml
urin
sampl
legionella
urin
antigen
ml
urin
sampl
sputum
gram
stain
cultur
antimicrobi
suscept
test
sampl
obtain
patient
abl
expector
purul
sampl
ii
receiv
prior
antibiot
treatment
pair
serolog
examin
influenzaoth
agent
acut
serum
collect
convalesc
sampl
obtain
interv
less
seven
day
ml
clot
blood
virolog
routin
recommend
bacteriolog
patient
influenzarel
pneumonia
accord
sever
ill
nonsever
pneumonia
score
routin
test
patient
respond
empir
antibiot
therapi
sputum
sampl
sent
gram
stain
cultur
antimicrobi
suscept
test
b
sever
pneumonia
score
bilater
cxr
chang
blood
cultur
prefer
antibiot
treatment
commenc
pneumococc
urin
antigen
ml
urin
sputum
gram
stain
cultur
antimicrobi
suscept
test
sampl
obtain
patient
abl
expector
purul
sampl
receiv
prior
antibiot
treatment
pair
serolog
examin
influenzaoth
agent
acut
serum
collect
convalesc
sampl
obtain
interv
less
seven
day
ml
clot
blood
tracheal
endotrach
aspir
sampl
avail
sent
gram
stain
cultur
antimicrobi
suscept
test
gener
manag
hypox
patient
receiv
appropri
oxygen
therapi
monitor
oxygen
satur
inspir
oxygen
concentr
aim
maintain
pao
kpa
sao
ge
high
concentr
oxygen
safe
given
uncompl
pneumonia
oxygen
therapi
patient
preexist
chronic
obstruct
pulmonari
diseas
complic
ventilatori
failur
guid
repeat
arteri
blood
ga
measur
noninvas
ventil
may
help
patient
without
preexist
copd
develop
respiratori
failur
niv
may
valu
bridg
invas
ventil
specif
circumst
level
bed
high
demand
respiratori
andor
critic
care
unit
experienc
use
niv
best
place
ensur
appropri
infect
control
measur
adopt
time
patient
assess
cardiac
complic
also
volum
deplet
need
addit
intraven
fluid
nutrit
support
given
sever
prolong
ill
temperatur
respiratori
rate
puls
blood
pressur
mental
statu
oxygen
satur
inspir
oxygen
concentr
monitor
record
initi
least
twice
daili
frequent
sever
ill
requir
regular
oxygen
therapi
earli
warn
score
system
conveni
way
perform
patient
progress
satisfactorili
full
clinic
reassess
repeat
chest
radiograph
recommend
patient
review
hour
prior
discharg
home
two
follow
unstabl
clinic
factor
consid
remain
hospit
temperatur
heart
rate
respiratori
rate
systol
blood
pressur
mmhg
oxygen
satur
inabl
maintain
oral
intak
abnorm
mental
statu
follow
clinic
review
consid
patient
suffer
signific
complic
signific
worsen
underli
diseas
either
gener
practition
hospit
clinic
discharg
follow
patient
offer
access
inform
ill
take
home
medic
follow
arrang
respons
hospit
team
arrang
follow
plan
patient
gener
practition
individu
consid
treatment
antivir
neuraminidas
inhibitor
follow
acut
influenzalik
ill
fever
symptomat
two
day
less
treatment
schedul
adult
oseltamivir
mg
everi
hour
five
day
dose
reduc
creatinin
clearanc
less
mlminut
ie
mg
od
patient
unabl
mount
adequ
febril
respons
eg
immunocompromis
elderli
may
still
elig
antivir
treatment
despit
lack
document
fever
hospitalis
patient
sever
ill
particularli
also
immunocompromis
may
benefit
antivir
treatment
start
hour
diseas
onset
although
evid
demonstr
benefit
lack
circumst
antibiot
manag
influenza
previous
well
adult
acut
bronchiti
complic
influenza
absenc
pneumonia
routin
requir
antibiot
antibiot
consid
previous
well
adult
develop
worsen
symptom
recrudesc
fever
increas
dyspnoea
patient
high
risk
complic
secondari
infect
appendix
consid
antibiot
presenc
lower
respiratori
featur
patient
adequ
treat
oral
antibiot
prefer
choic
includ
coamoxiclav
tetracyclin
macrolid
clarithromycin
erythromycin
fluoroquinolon
activ
streptococcu
pneumonia
staphylococcu
aureu
altern
choic
certain
circumst
patient
adequ
treat
oral
antibiot
oral
therapi
coamoxiclav
tetracyclin
prefer
oral
therapi
contraind
recommend
parenter
choic
includ
intraven
coamoxiclav
second
third
gener
cephalosporin
cefuroxim
cefotaxim
macrolid
erythromycin
clarithromycin
fluoroquinolon
activ
pneumonia
staph
aureu
altern
regimen
requir
eg
intoler
penicillin
current
levofloxacin
moxifloxacin
recommend
fluoroquinolon
licens
uk
antibiot
administ
within
four
hour
admiss
patient
sever
pneumonia
treat
immedi
diagnosi
parenter
antibiot
intraven
combin
broad
spectrum
blactamas
stabl
antibiot
coamoxiclav
second
eg
cefuroxim
third
eg
cefotaxim
gener
cephalosporin
togeth
macrolid
eg
clarithromycin
erythromycin
prefer
altern
regimen
includ
fluoroquinolon
enhanc
activ
pneumococci
togeth
broad
spectrum
blactamas
stabl
antibiot
macrolid
current
levofloxacin
fluoroquinolon
intraven
formul
licens
uk
patient
treat
initi
parenter
antibiot
transfer
oral
regimen
soon
clinic
improv
occur
temperatur
normal
hour
provid
contraind
oral
rout
patient
admit
hospit
non
sever
uncompl
pneumonia
seven
day
appropri
antibiot
recommend
sever
microbiolog
undefin
pneumonia
ten
day
treatment
propos
synopsi
clinic
manag
adult
refer
hospit
synopsi
main
recommend
pandem
flu
clinic
manag
patient
influenzalik
ill
influenza
pandem
extend
day
staph
aureu
gram
neg
enter
bacilli
pneumonia
suspect
confirm
nonsever
pneumonia
hospit
combin
therapi
chang
fluoroquinolon
effect
pneumococc
staphylococc
cover
option
ad
antibiot
effect
mrsa
option
sever
pneumonia
respond
combin
antibiot
therapi
high
fever
cough
influenzalik
symptom
children
seek
advic
commun
health
profession
featur
put
high
risk
complic
treat
oseltamivir
given
advic
antipyret
fluid
children
age
year
risk
complic
appendix
seen
gp
high
fever
cough
influenzalik
symptom
plu
risk
group
children
seen
gp
e
children
may
consid
increas
risk
complic
cough
fever
influenzalik
ill
temperatur
plu
either
chronic
comorbid
diseas
one
follow
featur
breath
difficulti
sever
earach
vomit
hour
drowsi
patient
offer
antibiot
well
oseltamivir
year
age
advic
antipyret
fluid
children
age
year
none
featur
treat
antipyret
fluid
low
threshold
antibiot
becom
unwel
indic
hospit
admiss
sign
respiratori
distress
markedli
rais
respiratori
rate
grunt
intercost
recess
breathless
chest
sign
cyanosi
sever
dehydr
alter
consciou
level
complic
prolong
seizur
sign
septicaemia
extrem
pallor
hypotens
floppi
infant
children
admit
hospit
like
need
oxygen
therapi
andor
intraven
support
well
antibiot
oseltamivir
indic
transfer
high
depend
intens
care
failur
maintain
sao
fio
child
shock
sever
respiratori
distress
rais
paco
kpa
rise
respiratori
rate
puls
rate
clinic
evid
sever
respiratori
distress
without
rais
paco
recurr
apnoea
slow
irregular
breath
evid
encephalopathi
picu
bed
avail
children
triag
basi
sever
acut
coexist
diseas
likelihood
achiev
full
recoveri
full
blood
count
differenti
urea
creatinin
electrolyt
liver
enzym
blood
cultur
done
sever
ill
children
cxr
perform
children
hypox
sever
ill
deterior
despit
treatment
puls
oximetri
perform
everi
child
assess
admiss
hospit
pneumonia
virolog
children
nasopharyng
aspir
nose
throat
swab
present
day
onset
ill
acut
serum
ml
clot
blood
collect
convalesc
sampl
ml
clot
blood
obtain
interv
less
day
bacteriolog
children
influenzarel
pneumonia
blood
cultur
antibiot
treatment
commenc
sputum
sampl
obtain
older
children
pair
serolog
examin
influenzaoth
agent
virolog
routin
recommend
bacteriolog
children
influenzarel
pneumonia
blood
cultur
antibiot
treatment
commenc
sputum
sampl
obtain
older
children
patient
whose
oxygen
satur
less
breath
air
treat
oxygen
given
nasal
cannula
head
box
face
mask
maintain
oxygen
satur
children
unabl
maintain
oral
intak
supplementari
fluid
possibl
given
enter
rout
intraven
fluid
sever
pneumonia
given
basal
level
children
safe
discharg
hospit
clearli
improv
physiolog
stabl
toler
oral
feed
respiratori
rate
infant
awak
oxygen
satur
air
set
pandem
children
consid
treatment
antivir
follow
acut
influenzalik
ill
fever
symptomat
two
day
less
oseltamivir
antivir
agent
choic
children
sever
ill
hospit
oseltamivir
may
use
child
symptomat
day
evid
demonstr
benefit
lack
circumst
children
risk
complic
influenza
b
diseas
sever
enough
merit
hospit
admiss
influenza
pandem
treat
antibiot
provid
cover
pneumonia
staph
aureu
h
influenza
children
year
coamoxiclav
drug
choic
clarithromycin
cefuroxim
use
children
allerg
penicillin
children
year
doxycyclin
altern
oral
antibiot
given
provid
oral
fluid
toler
children
sever
ill
pneumonia
complic
influenza
second
agent
ad
regim
eg
clarithromycin
cefuroxim
drug
given
intraven
ensur
high
serum
tissu
antibiot
level
facilit
prepared
plan
document
written
advanc
emerg
next
influenza
pandem
time
ident
caus
viru
remain
unknown
guidelin
base
best
evid
avail
previou
pandem
interpandem
influenza
period
guidanc
may
evolv
clinicopatholog
inform
eventu
pandem
viru
emerg
influenza
pandem
way
user
strongli
urg
refer
uptod
version
guidelin
webbas
access
point
season
influenza
familiar
infect
uk
especi
winter
everi
year
strain
influenza
type
b
circul
give
rise
clinic
consult
primari
care
agespecif
impact
vari
season
episod
hospit
treatment
mainli
older
person
young
children
occasion
work
age
adult
death
mainli
elderli
treatment
primari
care
hospit
may
requir
due
direct
effect
influenza
viru
infect
possibl
complic
commonli
secondari
bacteri
pneumonia
increas
gp
consult
influenzalik
ill
winter
bed
pressur
frequent
associ
period
known
commun
influenza
activ
pandem
influenza
occur
new
influenza
viru
subtyp
emerg
markedli
differ
recent
circul
subtyp
strain
abl
infect
human
spread
effici
person
person
caus
signific
clinic
ill
high
proport
infect
viru
novel
human
high
proport
popul
littl
immun
produc
larg
pool
suscept
person
accordingli
diseas
spread
wide
rapidli
influenza
pandem
occur
sporad
unpredict
devast
unusu
pandem
caus
influenza
spanish
flu
kill
million
peopl
worldwid
pandem
follow
less
devast
impact
nevertheless
sever
influenza
asian
flu
emerg
hong
kong
flu
produc
roughli
million
excess
death
worldwid
circumst
still
exist
new
influenza
viru
pandem
potenti
emerg
spread
longest
interv
far
record
pandem
year
unpredict
time
next
pandem
underlin
occurr
sever
larg
outbreak
highli
pathogen
avian
influenza
associ
epizoot
transmiss
human
far
seriou
massiv
unpreced
outbreak
highli
pathogen
influenza
affect
poultri
east
south
east
asia
late
still
continu
outbreak
far
associ
small
number
human
case
high
proport
death
recent
epidemiolog
virolog
chang
report
northern
vietnam
may
indic
viru
begin
adapt
human
although
emerg
strain
capac
spread
effici
human
neither
inevit
immin
intern
concern
increas
regard
possibl
avian
influenza
may
evolv
produc
next
pandem
event
develop
inform
creation
guidanc
develop
licens
new
class
drug
neuraminidas
inhibitor
activ
influenza
uk
govern
announc
plan
procur
million
treatment
cours
oseltamivir
tamiflu
use
uk
event
pandem
involv
manag
patient
influenza
intend
guidelin
also
valu
healthcar
practition
usual
manag
patient
influenza
may
call
upon
pandem
situat
modif
recommend
local
level
may
necessari
specif
instanc
guidelin
relev
manag
patient
affect
season
influenza
sporad
acut
exacerb
chronic
obstruct
pulmonari
diseas
aecopd
lower
respiratori
tract
infect
lrti
communityacquir
pneumonia
cap
primari
care
level
nation
oper
plan
includ
follow
three
broad
area
deem
import
clinic
manag
patient
influenza
b
manag
patient
demand
includ
patient
influenza
c
health
servic
deliveri
plan
guidelin
cover
first
area
serv
sourc
document
primari
care
oper
plan
primari
care
oper
plan
incorpor
three
area
within
singl
refer
develop
dh
collabor
rcgp
bma
even
though
imposs
predict
certainti
impact
next
pandem
base
upon
avail
epidemiolog
model
inform
clear
gener
demand
health
care
may
satur
overwhelm
normal
nh
acut
servic
period
time
perhap
sever
week
month
accordingli
anticip
nh
common
health
system
around
world
need
revert
emerg
arrang
laid
detail
oper
guidanc
health
servic
planner
uk
oper
framework
stockpil
distribut
use
antivir
drug
event
pandem
influenza
primari
care
oper
plan
regard
deliveri
medic
care
patient
influenza
normal
achiev
gp
treatment
commun
patient
well
enough
manag
commun
hospit
care
acut
medicin
person
consid
ill
manag
home
event
pandem
follow
addit
care
set
may
consid
threshold
hospit
admiss
rise
treatment
patient
commun
would
normal
receiv
care
gp
healthcar
profession
nurs
paramed
pharmacist
etc
follow
treatment
guidanc
laid
public
use
prescriptiononli
medicin
accord
patient
group
direct
pgd
treatment
patient
home
temporari
intermedi
care
facil
gp
follow
treatment
guidanc
laid
public
normal
circumst
patient
would
admit
hospit
care
treatment
sever
ill
patient
hospit
medic
nurs
team
normal
manag
patient
influenza
communityacquir
pneumonia
area
hospit
normal
use
provid
medic
care
exampl
surgic
team
bed
space
divert
routin
elect
work
toward
pandem
respons
recommend
offer
current
guidelin
base
matrix
evid
centr
mainli
around
season
influenza
expert
opinion
group
consensu
grade
recommend
base
strength
evid
base
deem
inappropri
section
epidemiolog
health
impact
project
scale
sever
ill
henc
consequ
caus
pandem
influenza
gener
exceed
even
sever
winter
epidem
mortal
uk
like
exceed
death
possibl
appreci
higher
besid
elderli
excess
mortal
also
like
younger
adult
children
model
studi
suggest
case
occur
hong
kong
intern
travel
take
less
one
month
viru
reach
uk
case
begin
occur
uk
take
two
three
week
activ
widespread
roughli
three
week
six
week
initi
case
uk
activ
peak
possibl
one
epidem
wave
interv
sever
month
second
wave
occur
may
sever
first
cumul
clinic
serolog
attack
rate
across
wave
togeth
may
order
respect
increas
demand
healthcar
servic
like
substanti
primari
care
hospit
set
influenza
pandem
occur
substanti
proport
possibl
popul
like
nonimmun
produc
larg
pool
suscept
person
past
pandem
scale
sever
ill
henc
consequ
variabl
broadli
epidemiolog
health
impact
project
introductori
observ
higher
order
even
sever
winter
epidem
reason
expect
case
next
pandem
well
excess
mortal
due
influenza
occur
winter
season
especi
mark
epidem
averag
annual
excess
mortal
attribut
influenza
recent
year
around
death
per
annum
england
wale
although
consider
yearli
variat
year
notabl
much
higher
averag
est
epidem
excess
mortal
england
wale
associ
three
pandem
twentieth
centuri
also
vari
wide
estim
civilian
season
consid
associ
influenza
pandem
estim
death
respect
therefor
extent
mortal
associ
next
pandem
reliabl
predict
although
reason
plan
scenario
wors
sever
winter
epidem
normal
influenza
typic
chang
agedistribut
case
compar
season
influenza
mortal
typic
season
influenza
usual
confin
age
group
year
tend
increas
younger
age
group
size
increas
morbid
mortal
extent
shift
age
distribut
occur
depend
varieti
factor
includ
natur
pandem
viru
preexist
immun
appear
consist
phenomenon
therefor
clinician
expect
see
rel
larger
amount
influenzarel
ill
younger
adult
compar
normal
winter
activ
least
one
third
excess
death
may
expect
person
year
age
virolog
clinic
surveil
influenza
improv
markedli
sinc
last
pandem
howev
extent
intern
travel
also
grown
model
studi
use
transmiss
characterist
base
pandem
intern
airtraff
data
indic
approxim
delay
first
case
hong
kong
first
introduct
uk
less
one
month
term
spread
within
uk
probabl
take
two
three
week
initi
introduct
activ
widespread
three
week
six
week
initi
uk
case
activ
peak
tempor
spatial
spread
pandem
strain
import
particularli
term
demand
place
healthcar
servic
pandem
activ
take
form
brief
sever
peak
case
difficult
servic
cope
compar
ident
number
case
distribut
longer
time
cours
exampl
pandem
long
first
wave
occur
winter
morbid
mortal
approxim
level
previou
season
influenza
follow
winter
short
sever
epidem
occur
threefold
higher
peak
gener
practic
consult
rate
fourfold
higher
peak
mortal
attribut
influenza
bronchiti
pneumonia
high
peak
consult
rate
well
illustr
fig
pandem
occur
three
distinct
epidem
wave
earli
spring
autumn
introductori
observ
epidemiolog
health
impact
project
provision
guidelin
bisbtshpa
collabor
depart
health
version
octob
late
winter
second
wave
far
largest
casefat
rate
also
higher
first
wave
pandem
caus
epidem
wave
winter
sever
one
contrast
second
wave
pandem
uk
small
comparison
first
thu
consid
possibl
one
wave
influenza
occur
within
month
emerg
pandem
viru
subsequ
wave
could
wors
first
imposs
predict
reliabl
precis
level
excess
mortal
experienc
next
pandem
howev
tabl
illustr
broad
rang
excess
mortal
reason
consid
base
variou
realist
combin
case
fatal
rate
clinic
attack
rate
deriv
previou
pandem
epidem
case
fatal
rate
correspond
aggreg
rate
observ
recent
epidem
season
pandem
although
overal
casefat
rate
observ
pandem
region
clinic
attack
rate
around
correspond
approxim
clinic
attack
rate
seen
three
previou
pandem
twentieth
centuri
thu
figur
least
excess
death
like
use
mathemat
project
possibl
illustr
potenti
impact
next
pandem
amount
accur
predict
tabl
summaris
number
event
might
expect
gp
patient
hisher
list
pct
serv
popul
person
use
assumpt
tabl
illustr
number
event
week
assum
singl
wave
pandem
period
typic
pct
popul
major
acut
trust
receiv
patient
catchment
area
span
sever
pct
figur
requir
prorata
adjust
appli
individu
hospit
section
clinic
featur
adult
influenza
clinic
defin
presenc
fever
new
chronic
lung
diseas
worsen
cough
acut
onset
context
influenza
circul
commun
clinic
definit
may
modifi
pandem
occur
spectrum
clinic
diseas
associ
pandem
strain
forecast
pneumonia
either
primari
viral
secondari
bacteri
commonest
complic
influenza
adult
neurolog
complic
rare
adult
clinic
manifest
infect
influenza
virus
divers
rang
asymptomat
infect
fulmin
respiratori
distress
lead
respiratori
failur
death
furthermor
presenc
influenzalik
ill
ili
compris
combin
fever
cough
sore
throat
myalgia
headach
specif
influenza
infect
respiratori
pathogen
may
present
ili
includ
virus
respiratori
syncyti
viru
rsv
adenoviru
rhinoviru
parainfluenza
viru
well
bacteri
pathogen
chlamydia
pneumonia
legionella
sp
mycoplasma
pneumonia
streptococcu
pneumonia
studi
examin
valu
clinic
definit
ili
diagnosi
influenza
infect
alway
use
clinic
definit
ili
includ
differ
studi
popul
make
comparison
studi
complic
systemat
review
literatur
area
identifi
threefold
combin
presenc
fever
cough
acut
onset
predict
clinic
featur
accuraci
clinic
definit
higher
person
age
year
compar
patient
group
without
age
restrict
posit
likelihood
ratio
ci
vs
probabl
influenza
infect
also
increas
increas
level
fever
importantli
predict
valu
clinic
definit
base
ili
increas
influenza
viru
known
circul
commun
cohort
studi
correl
ili
laboratoryconfirm
influenza
infect
rang
clinic
trial
rate
consist
report
find
relat
influenza
infect
interpandem
period
global
influenza
pandem
pandem
strain
known
circul
local
immunolog
suscept
popul
presenc
ili
would
expect
highli
predict
influenza
infect
howev
extent
clinic
diagnosi
ili
becom
predict
pandem
also
determin
behaviour
public
mani
would
normal
present
health
profession
prompt
present
predict
valu
clinic
diagnosi
ili
reduc
follow
descript
relat
mainli
interpandem
influenza
infect
influenza
b
c
consid
pandem
threat
differ
strain
may
associ
differ
clinic
present
diseas
sever
instanc
evid
suggest
subtyp
caus
sever
diseas
subtyp
spectrum
clinic
diseas
associ
new
influenza
subtyp
eg
pandem
strain
determin
current
may
differ
describ
interpandem
influenza
incub
period
prior
onset
symptom
commonli
two
four
day
rang
day
adult
ill
typic
present
abrupt
onset
fever
accompani
rang
symptom
list
box
fever
paramount
symptom
may
reach
although
usual
rang
peak
occur
within
hour
onset
last
typic
three
day
rang
day
cough
gener
dri
although
case
may
product
product
cough
togeth
chest
tight
substern
sore
common
patient
underli
chronic
lung
diseas
myalgia
affect
mainli
back
limb
gastrointestin
symptom
vomit
diarrhoea
uncommon
adult
abdomin
pain
rare
clinic
find
includ
toxic
appear
initi
stage
hot
moist
skin
flush
face
inject
eye
hyperaem
mucou
membran
around
nose
pharynx
tender
cervic
lymphadenopathi
found
minor
case
wheez
lung
crackl
recognis
find
commonli
note
patient
coexist
chronic
lung
diseas
although
overal
clinic
pictur
uncompl
influenza
specif
age
group
similar
differ
influenza
subtyp
frequenc
certain
symptom
may
vari
instanc
asian
pandem
headach
sore
throat
frequent
initi
symptom
uncompl
infect
ill
usual
resolv
seven
day
although
cough
malais
lassitud
may
persist
week
influenza
viru
infect
associ
worsen
clinic
condit
patient
rang
exist
medic
condit
heart
failur
diabet
coronari
heart
diseas
asthma
chronic
obstruct
airway
diseas
copd
addit
specif
complic
associ
influenza
infect
regardless
coexist
medic
condit
recognis
tabl
base
data
interpandem
influenza
certain
person
identifi
high
risk
influenzarel
complic
patient
similar
group
current
recommend
influenza
vaccin
depart
health
includ
age
chronic
respiratori
diseas
includ
asthma
chronic
heart
diseas
chronic
renal
diseas
chronic
liver
diseas
immunosuppress
due
diseas
treatment
diabet
mellitu
age
year
older
long
stay
residenti
care
see
appendix
cours
pandem
may
emerg
patient
group
high
risk
complic
differ
group
current
identifi
circumst
detail
high
risk
patient
group
alter
accord
relev
clinicoepidemiolog
data
incid
pneumonia
defin
combin
respiratori
symptom
sign
support
chest
radiograph
chang
consist
infect
complic
influenza
infect
vari
wide
depend
viral
host
factor
pneumonia
gener
occur
frequent
greater
sever
patient
preexist
chronic
cardiac
respiratori
condit
patient
develop
pneumonia
may
present
symptom
sign
indistinguish
pneumonia
relat
viral
bacteri
pathogen
context
influenza
pandem
presenc
ili
new
worsen
dyspnoea
prompt
care
examin
presenc
complic
pneumonia
two
main
type
influenzarel
pneumonia
recognis
primari
viral
pneumonia
secondari
bacteri
pneumonia
patient
primari
viral
pneumonia
typic
becom
breathless
within
first
hour
onset
fever
initi
dri
cough
may
becom
product
bloodstain
sputum
cyanosi
tachypnoea
bilater
crepit
wheez
chest
examin
leucocytosi
usual
commonest
chest
radiograph
abnorm
bilater
interstiti
infiltr
predominantli
midzon
although
focal
consolid
also
well
recognis
rapid
clinic
deterior
respiratori
failur
may
ensu
mortal
hospitalis
patient
high
despit
maximum
support
treatment
intens
care
major
fatal
case
death
occur
within
seven
day
hospit
admiss
secondari
bacteri
pneumonia
common
four
time
primari
viral
pneumonia
typic
symptom
sign
pneumonia
develop
earli
convalesc
period
four
five
day
onset
initi
symptom
other
symptom
pneumonia
blend
initi
symptom
influenza
chest
radiographi
usual
demonstr
lobar
pattern
consolid
mortal
rate
rang
although
small
studi
report
higher
mortal
rate
spectrum
pathogen
implic
similar
observ
cap
includ
streptococcu
pneumonia
staphylococcu
aureu
haemophilu
influenza
group
c
g
bhaemolyt
streptococci
differ
pathogen
predomin
differ
time
instanc
pandem
h
influenza
bhaemolyt
streptococci
pneumonia
predomin
pathogen
isol
pneumonia
predomin
pathogen
follow
staph
aureu
nontyp
h
influenza
notabl
staph
aureu
identifi
two
half
time
frequent
pandem
compar
pneumonia
occur
interpandem
period
secondari
staphylococc
pneumonia
associ
higher
incid
lung
abscess
format
vs
carri
poorer
prognosi
compar
nonstaphylococc
pneumonia
mortal
vs
pandem
staph
aureu
predomin
bacteri
pathogen
isol
fatal
case
influenzarel
pneumonia
case
seri
bacteri
viral
pneumonia
occur
concurr
instanc
chest
radiograph
may
demonstr
lobar
consolid
superimpos
bilater
diffus
lung
infiltr
mortal
rate
mix
viral
bacteri
pneumonia
high
primari
viral
pneumonia
minor
abnorm
ecg
st
segment
deviat
wave
chang
rhythm
disturb
describ
uncompl
influenza
ill
report
patient
hospitalis
influenza
cardiac
symptom
myocard
pericard
occasion
encount
sever
ill
post
mortem
evid
necrotis
myocard
report
patient
without
clinic
signific
myocard
antemortem
period
contrast
myalgia
affect
back
limb
common
initi
present
myositi
gener
develop
subsid
acut
upper
respiratori
tract
symptom
gastrocnemiu
soleu
muscl
typic
involv
pain
tender
palpat
complet
recoveri
usual
occur
three
day
elev
serum
creatin
phosphokinas
recognis
rare
associ
myoglobinuria
renal
failur
myositi
commonli
describ
children
adult
central
nervou
system
cn
involv
adult
uncommon
report
origin
japan
occur
children
main
clinic
syndrom
enceph
encephalopathi
manifest
form
decreas
conscious
seizur
three
day
rang
day
follow
onset
upper
respiratori
tract
symptom
focal
neurolog
sign
paresi
aphasia
choreoathetosi
cranial
nerv
palsi
less
common
cerebrospin
fluid
csf
examin
may
normal
reveal
elev
protein
white
cell
count
imag
ct
mri
may
normal
indic
good
prognosi
full
recoveri
may
anticip
young
age
abnorm
ctmri
find
associ
poor
outcom
includ
death
recoveri
sever
neurolog
sequela
fuller
descript
given
section
acut
necrotis
encephalopathi
rare
fulmin
syndrom
associ
multifoc
brain
lesion
describ
mainli
japan
rare
manifest
includ
transvers
myeliti
guillain
syndrom
rey
syndrom
characteris
encephalopathi
acut
fatti
liver
associ
aspirin
use
high
mortal
special
situat
almost
exclus
seen
children
adolesc
nevertheless
physician
manag
adult
advis
awar
complic
fuller
descript
given
section
complic
rare
encount
adult
influenza
infect
includ
toxic
shock
syndrom
conjunct
secondari
staph
aureu
infect
parot
otiti
media
commonli
encount
children
adult
human
infect
caus
differ
avian
influenza
virus
past
includ
recent
year
outbreak
human
infect
novel
strain
avian
influenza
rais
particular
concern
global
regard
risk
human
pandem
concern
due
part
recognit
avian
influenza
pass
directli
bird
human
b
human
avian
influenza
caus
sever
diseas
high
mortal
full
spectrum
human
ill
associ
avian
influenza
infect
complet
known
descript
clinic
featur
influenza
infect
human
base
larg
case
seri
hospitalis
patient
subclin
infect
mild
ill
atyp
present
influenza
infect
human
report
frequenc
infect
difficult
determin
hospitalis
patient
ili
similar
associ
season
influenza
infect
recognis
gastrointestin
symptom
present
rel
larg
proport
adult
paediatr
case
contrast
rel
low
incid
gastrointestin
symptom
season
influenza
major
patient
develop
sever
primari
viral
pneumonia
usual
associ
lymphopenia
thrombocytopenia
derang
liver
function
test
renal
failur
multiorgan
failur
may
develop
subsequ
mortal
high
detail
descript
given
appendix
influenza
acquir
effici
humantohuman
transmiss
capabl
may
result
influenza
pandem
event
clinic
featur
human
diseas
may
alter
commonest
present
featur
influenza
epidem
fever
cough
rhinorrhoea
infant
fever
nonspecif
symptom
diarrhoea
vomit
common
older
children
pharyng
headach
frequent
clinic
featur
influenza
children
pandem
forecast
children
underli
respiratori
cardiac
diseas
immun
compromis
nonambul
like
sever
affect
younger
child
like
hospit
admiss
need
clinic
featur
influenza
present
pandem
predict
appear
depend
strain
influenza
respect
host
new
strain
influenza
respons
epidem
pandem
may
result
differ
spectrum
clinic
featur
previou
strain
common
featur
previou
epidem
describ
depend
age
child
studi
clinic
featur
hospit
base
therefor
like
reflect
sever
ill
nevertheless
inform
one
main
issu
pandem
patient
requir
hospit
admiss
young
children
present
primari
care
nonpandem
influenza
season
specif
clinic
featur
distinguish
influenza
winter
virus
neonat
may
present
nonspecif
sign
sepsi
pallor
floppi
poor
peripher
circul
poor
tone
lethargi
poor
feed
episod
apnoea
fever
may
present
featur
north
american
studi
identifi
influenza
common
reason
children
age
day
admit
hospit
epidem
fever
clinic
featur
fever
may
present
featur
age
group
may
also
irrit
toxic
like
older
children
present
gastrointestin
symptom
diarrhoea
vomit
febril
convuls
particularli
repeat
convuls
posit
associ
influenza
otiti
media
also
common
complic
children
admiss
rate
two
year
old
time
higher
children
age
year
present
differ
significantli
adult
common
featur
sudden
onset
high
fever
chill
cough
headach
sore
throat
fatigu
nasal
stuffi
conjunct
fever
tend
settl
two
four
day
later
though
dri
cough
clear
nasal
discharg
last
one
two
week
clinic
predict
model
north
america
influenza
children
shown
triad
cough
headach
pharyng
sensit
specif
posit
viral
cultur
influenza
subject
mean
age
six
year
present
epidem
suburban
emerg
depart
febril
respiratori
ill
one
symptom
influenza
finnish
retrospect
studi
children
refer
hospit
influenza
confirm
antigen
test
report
median
age
influenza
two
year
common
featur
cough
fever
rhinorrhoea
also
commonest
featur
report
chines
studi
mean
age
subject
influenza
four
year
condit
children
tabl
ambul
experi
substanti
morbid
influenza
season
disproportion
number
requir
inpati
care
ventilatori
support
tabl
adult
influenza
present
either
primari
viral
pneumonia
bacteri
pneumonia
commonli
caus
pneumonia
staph
aureu
much
less
publish
pneumonia
complic
influenza
children
outbreak
sever
pneumococc
pneumonia
children
occur
iowa
winter
coincid
epidem
influenza
compar
control
patient
time
like
rare
experienc
recent
influenzalik
ill
also
like
famili
member
ill
posit
serolog
convalesc
period
mani
patient
requir
chest
drainag
anoth
studi
children
proven
influenza
report
chest
radiograph
either
radiograph
evid
viral
pneumonia
normal
radiograph
child
lobar
pneumonia
report
evid
recent
outbreak
avian
influenza
hong
kong
vietnam
suggest
children
mild
diseas
other
appear
multiorgan
diseas
includ
acut
respiratori
distress
syndrom
ard
children
develop
progress
pneumonia
ard
die
report
bacteri
pneumonia
reason
believ
apart
ard
pneumonia
complic
influenza
present
differ
communityacquir
pneumonia
children
gener
clinic
indic
sever
assess
lower
respiratori
tract
infect
summaris
bt
guidelin
appendix
failur
improv
follow
hour
antibiot
deterior
includ
new
distinct
spike
fever
also
treat
sever
complic
factor
sought
clinic
cours
croup
caus
influenza
appear
sever
croup
caus
common
parainfluenza
viru
like
complic
bacteri
tracheiti
influenza
well
recognis
caus
otiti
media
commonest
bacteri
superinfect
influenza
report
approxim
patient
age
year
influenza
rank
second
respiratori
syncyti
viru
caus
bronchiol
clinic
featur
children
influenza
may
present
febril
convuls
commun
studi
netherland
recurr
febril
seizur
posit
relat
influenza
recommend
children
previou
febril
convuls
immunis
influenza
complic
describ
small
case
seri
defin
depress
alter
level
conscious
includ
lethargi
andor
extrem
irrit
younger
children
signific
chang
person
behaviour
persist
beyond
hr
confus
older
children
encephalopathi
usual
present
seizur
within
sever
day
onset
fever
seizur
point
usual
first
symptom
involv
central
nervou
system
febril
convuls
like
repeat
influenza
caus
fever
gener
occur
onset
fever
disturb
behaviour
neurolog
deficit
report
rapid
sever
clinic
cours
usual
encephalopathi
thought
due
brain
oedema
mediat
cytokin
rather
direct
invas
brain
steroid
therefor
consid
children
encephalopathi
recognis
japan
death
occur
residu
neurolog
deficit
full
recoveri
rare
childhood
acut
encephalopathi
associ
liver
dysfunct
caus
unknown
typic
follow
viral
ill
clear
associ
aspirin
therapi
thu
innat
suscept
coupl
aspirin
taken
relief
viral
symptom
influenza
particularli
influenza
b
commonli
implic
dramat
fall
incid
follow
warn
aspirin
use
children
possibl
children
long
term
aspirin
treatment
medic
condit
may
increas
risk
develop
influenza
infect
rey
syndrom
characteris
protract
vomit
encephalopathi
afebril
patient
minim
absent
jaundic
hepatomegali
patient
compris
acut
noninflammatori
encephalopathi
alter
level
conscious
elev
ammonia
level
hour
onset
mental
statu
chang
frequent
laboratori
abnorm
hepat
dysfunct
liver
biopsi
show
fatti
metamorphosi
threefold
increas
alanin
aminotransferas
alt
aspart
aminotransferas
ast
neurolog
symptom
usual
occur
hour
onset
vomit
lethargi
usual
first
neurolog
manifest
diarrhoea
hyperventil
may
first
sign
children
younger
two
year
investig
head
ct
scan
may
reveal
cerebr
oedema
result
usual
normal
electroencephalogram
eeg
may
reveal
slow
wave
activ
earli
stage
flatten
wave
advanc
stage
cerebrospin
fluid
may
may
increas
open
pressur
white
blood
cell
wbc
fewer
usual
lymphocyt
specif
treatment
rey
syndrom
key
aspect
manag
correct
metabol
imbal
reduct
intracrani
pressur
advic
request
specialist
metabol
medicin
mani
children
underli
inborn
error
metabol
mortal
fallen
less
result
earlier
diagnosi
aggress
therapi
acut
necrotis
encephalopathi
ane
occur
mainli
japan
first
describ
estim
death
per
annum
relat
central
nervou
system
complic
influenza
japan
suggest
either
genet
predisposit
complic
variat
strain
influenza
circul
japan
ane
characteris
high
fever
convuls
coma
children
age
one
five
year
onset
two
four
day
respiratori
symptom
fewer
patient
surviv
specif
marker
although
patient
rais
liver
transaminas
mani
csf
normal
symmetr
multifoc
brain
lesion
seen
bilater
thalam
involv
characterist
may
demonstr
mri
defin
encephalopathi
plu
two
follow
fever
higher
seizur
focal
neurolog
find
wbc
cellsml
csf
eeg
find
consist
enceph
abnorm
neuroimag
must
consid
child
present
alter
level
conscious
irrit
good
evid
increas
risk
meningococc
diseas
follow
influenza
infect
pandem
focu
diagnos
influenzarel
ill
neurolog
condit
drug
toxic
exampl
may
miss
literatur
review
case
myositi
suggest
complic
mainli
schoolchildren
calf
muscl
predominantli
affect
rhabdomyolysi
renal
failur
rare
also
rare
complic
describ
children
underli
medic
condit
section
gener
manag
investig
primari
care
widespread
concern
pandem
significantli
increas
demand
advic
consult
anticip
like
significantli
higher
consult
rate
type
respiratori
tract
infect
includ
normal
manag
well
home
use
overthecount
remedi
eg
febril
cold
sore
throat
temperatur
consequ
demand
manag
practic
pct
crucial
avoid
servic
capac
triag
care
overwhelm
guidanc
demand
manag
health
servic
deliveri
given
primari
care
oper
plan
see
section
manag
decis
patient
influenza
base
primarili
assess
ill
sever
identif
whether
individu
risk
group
current
advic
dohloc
public
health
offici
base
epidemiolog
pandem
patient
consid
high
risk
featur
suggest
sever
diseas
complic
may
need
seen
face
face
consult
primari
care
clinician
patient
present
gener
practic
symptom
suggest
influenza
except
perhap
urgent
admiss
requir
given
gener
advic
advic
symptomat
treatment
import
clinician
identifi
address
individu
concern
expect
provid
inform
ill
provid
inform
patient
help
seek
help
use
fact
provid
patient
includ
box
littl
scientif
evid
symptomat
selfhelp
treatment
experi
suggest
follow
may
help
unlik
caus
harm
treat
fever
myalgia
headach
paracetamol
ibuprofen
rest
drink
plenti
fluid
avoid
smoke
consid
short
cours
topic
decongest
throat
lozeng
salin
nose
drop
mani
infant
children
cough
mild
fever
may
due
infect
respiratori
syncyti
viru
especi
winter
month
children
manag
usual
way
home
parent
antipyret
fluid
note
aspirin
use
children
manag
children
determin
diseas
sever
see
appendix
principl
symptomat
manag
similar
adult
box
inform
influenza
provid
patient
influenza
caus
number
differ
type
influenza
virus
incub
period
typic
one
four
day
infect
adult
usual
contagi
day
ill
onset
five
day
children
typic
contagi
seven
day
although
sometim
longer
fever
usual
declin
two
three
day
normal
disappear
sixth
day
cough
weak
fatigu
persist
one
two
week
six
week
antibiot
benefit
peopl
influenza
sometim
need
treat
secondari
infect
import
note
inform
may
modifi
pandem
occur
fever
four
five
day
start
get
better
get
wors
start
feel
better
develop
high
fever
feel
unwel
take
antivir
drug
eg
oseltamivir
symptom
start
improv
within
two
day
lack
improv
two
day
start
antivir
drug
indic
reconsult
import
note
inform
may
modifi
pandem
occur
children
one
year
age
year
high
risk
complic
see
appendix
seen
assess
gp
e
depart
children
one
seven
year
age
may
seen
nurs
gp
age
seven
year
may
seen
member
commun
health
team
eg
commun
pharmacist
children
parent
given
advic
antipyret
fluid
aspirin
contraind
children
age
year
exampl
prompt
patient
reconsult
given
box
patient
start
antivir
agent
see
section
indic
antivir
use
would
expect
begin
improv
within
hour
start
treatment
failur
improv
two
day
start
antivir
agent
indic
reconsult
time
reconsult
altern
diagnosi
consid
well
occurr
influenzarel
complic
rapid
deterior
follow
first
consult
prompt
patient
reconsult
failur
improv
two
day
start
antivir
agent
indic
reconsult
first
consult
involv
contact
physician
reconsult
prefer
involv
physician
usual
gp
gener
investig
done
commun
gener
investig
includ
chest
xray
necessari
major
patient
manag
commun
aim
microbiolog
investig
earli
pandem
uk
alert
level
confirm
influenza
circul
local
commun
pandem
establish
uk
alert
level
microbiolog
investig
recommend
routin
like
avail
readili
routin
test
bacteri
pathogen
recommend
stage
possibl
earli
pandem
uk
alert
level
nose
throat
swab
nasopharyng
swab
children
viru
transport
medium
submit
local
laboratori
pandem
establish
uk
alert
level
microbiolog
investig
recommend
section
criteria
hospit
referr
adult
requir
hospit
referr
adult
uncompl
influenza
infect
usual
requir
hospit
referr
patient
might
requir
hospit
admiss
fall
two
main
group
worsen
preexist
medic
condit
influenzarel
complic
patient
experi
worsen
clinic
deterior
preexist
medic
problem
due
influenza
infect
manag
accord
recommend
best
practic
medic
condit
question
instanc
patient
acut
exacerb
copd
trigger
influenza
infect
manag
accord
current
nice
guidelin
copd
worsen
preexist
condit
like
group
high
risk
influenzarel
respiratori
complic
consequ
risk
criteria
hospit
referr
part
clinic
manag
primari
care
pandem
flu
clinic
manag
patient
influenzalik
ill
influenza
pandem
group
promptli
reassess
ill
get
wors
consid
hospit
referr
pneumonia
commonest
influenzarel
complic
requir
hospit
admiss
patient
complain
new
worsen
dyspnoea
care
assess
sign
pneumonia
pneumonia
diagnos
diseas
sever
assess
recommend
hospit
referr
made
accordingli
valid
sever
assess
tool
develop
specif
influenzarel
pneumonia
score
tabl
well
valid
sever
assess
tool
develop
patient
communityacquir
pneumonia
cap
recommend
british
thorac
societi
cap
guidelin
use
commun
set
offer
exampl
assess
tool
influenzarel
pneumonia
use
sever
assess
tool
replac
clinic
judgement
patient
social
circumst
also
alway
taken
account
view
rapid
fulmin
cours
primari
viral
pneumonia
patient
pneumonia
bilater
chest
sign
crackl
consid
hospit
referr
influenzarel
complic
uncommon
specif
recommend
relat
criteria
hospit
admiss
diseas
sever
assess
case
patient
clinic
defin
uncompl
influenza
infect
would
expect
make
full
recoveri
requir
good
symptomat
manag
access
antivir
treatment
inform
natur
histori
advic
reconsult
patient
new
worsen
symptom
particularli
short
breath
recrudesc
fever
respond
treatment
examin
assess
presenc
sever
influenzarel
pneumonia
patient
worsen
preexist
comorbid
medic
condit
manag
accord
best
practic
condit
refer
publish
diseasespecif
guidelin
avail
patient
influenzarel
pneumonia
clinic
hospit
referr
assess
consid
patient
score
particularli
score
urgent
admiss
score
patient
bilater
chest
sign
pneumonia
refer
hospit
assess
regardless
score
score
replac
clinic
judgment
antivir
treatment
choic
oseltamivir
tamiflu
tm
given
fiveday
cours
oral
tablet
mg
twice
daili
adult
liquid
suspens
avail
children
age
one
year
upward
see
tabl
clinic
trial
data
accru
date
base
season
interpandem
influenza
anticip
posit
effect
antivir
pandem
reduct
ill
durat
hour
therefor
rapid
mobilis
affect
individu
includ
essenti
worker
b
possibl
reduct
hospitalis
infect
individu
c
reduct
subsequ
antibiot
use
infect
individu
evid
accru
date
suggest
reduct
overal
mortal
rule
receiv
antivir
drug
ideal
antivir
treatment
offer
everi
patient
one
year
age
acut
influenzalik
ill
b
fever
adult
children
c
present
within
hour
onset
symptom
except
patient
unabl
mount
adequ
febril
respons
eg
immunocompromis
elderli
may
still
elig
antivir
treatment
despit
lack
document
fever
ii
immunosuppress
patient
includ
longterm
corticosteroid
therapi
may
suffer
prolong
viraemia
could
possibl
benefit
antivir
therapi
commenc
later
hour
onset
ili
iii
patient
sever
ill
hospitalis
due
nonclin
reason
may
benefit
antivir
therapi
commenc
later
hour
onset
ili
strong
evid
support
antivir
use
except
situat
commonest
advers
effect
oseltamivir
nausea
patient
manag
mild
antiemet
medic
sideeffect
list
appendix
nation
distribut
arrang
laid
uk
oper
framework
stockpil
distribut
use
antivir
drug
event
pandem
influenza
primari
care
oper
plan
drug
made
avail
arrang
pharmaci
pct
andor
gp
surgeri
pct
encourag
plan
deliveri
antivir
larg
number
previous
healthi
person
ili
via
commun
health
profession
includ
commun
pharmacist
gp
focu
effort
assess
manag
person
high
risk
complic
see
appendix
patient
develop
complic
section
antibiot
use
primari
care
use
antibiot
adult
influenza
complic
pneumonia
determin
presenc
comorbid
ill
b
time
first
consult
respect
onset
symptom
featur
acut
bronchiti
cough
retrostern
discomfort
wheez
sputum
product
integr
part
influenz
ill
previous
well
individu
pneumonia
new
focal
chest
sign
antibiot
indic
patient
seen
later
cours
ill
ill
worsen
instanc
recrudesc
fever
increas
breathless
worsen
bacteri
bronchiti
antibiot
use
primari
care
part
clinic
manag
primari
care
pandem
flu
clinic
manag
patient
influenzalik
ill
influenza
pandem
develop
pneumonia
possibl
use
antibiot
consid
select
patient
delay
antibiot
prescript
may
offer
first
consult
antibiot
prescript
come
clear
instruct
antibiot
use
ill
start
settl
two
day
worsen
symptom
potenti
advantag
approach
delay
antibiot
prescript
minimis
rate
reconsult
robust
data
regard
effect
approach
incid
influenzarel
complic
high
risk
influenzarel
complic
chronic
obstruct
pulmonari
diseas
copd
andor
b
sever
comorbid
diseas
strongli
consid
antibiot
first
consult
start
antibiot
patient
begin
improv
next
hour
antibiot
treatment
get
wors
advis
recontact
gp
assess
pneumonia
sever
see
section
antibiot
cover
like
bacteri
pathogen
includ
pneumonia
h
influenza
catarrhali
staph
aureu
prefer
first
choic
antibiot
nonpneumon
bronchial
infect
includ
patient
copd
includ
effect
oral
blactamas
stabl
agent
tetracyclin
eg
doxycyclin
coamoxiclav
macrolid
eg
erythromycin
clarithromycin
altern
intoler
prefer
first
choic
whilst
rememb
possibl
antimicrobi
resist
clarithromycin
better
activ
h
influenza
azithromycin
detail
regard
principl
antibiot
use
includ
antibiot
resist
pattern
given
section
patient
without
sever
preexist
ill
uncompl
influenza
simpl
bronchiti
routin
requir
antibiot
patient
without
sever
preexist
ill
seen
later
cours
ill
develop
signific
worsen
symptom
particularli
recrudesc
fever
increas
breathless
consid
antibiot
patient
copd
andor
sever
preexist
ill
therefor
high
risk
influenzarel
complic
strongli
consid
antibiot
first
consult
patient
adequ
treat
week
cours
oral
antibiot
prefer
choic
antibiot
need
also
cover
infect
staph
aureu
exampl
either
doxycyclin
coamoxiclav
see
tabl
macrolid
eg
erythromycin
clarithromycin
altern
choic
certain
circumst
principl
antibiot
select
patient
influenzarel
pneumonia
manag
commun
similar
manag
sporad
communityacquir
pneumonia
gener
except
adequ
cover
staph
aureu
addit
cover
pneumonia
includ
empir
regimen
reason
tetracyclin
doxycyclin
oral
coamoxiclav
prefer
regimen
tabl
macrolid
eg
erythromycin
clarithromycin
altern
intoler
prefer
first
choic
macrolid
erythromycin
mg
qd
po
clarithromycin
mg
bd
b
po
altern
regimen
provid
intoler
hypersensit
prefer
regimen
b
clarithromycin
may
substitut
gastrointestin
intoler
oral
erythromycin
also
benefit
twice
daili
dosag
better
cover
h
influenza
abbrevi
od
daili
bd
twice
td
time
qd
time
secondari
bacteri
infect
particularli
pneumonia
otiti
media
common
children
influenza
pneumonia
staph
aureu
h
influenza
common
pathogen
encount
influenza
outbreak
children
one
follow
group
treat
antibiot
provid
cover
pneumonia
staph
aureu
h
influenza
risk
complic
influenza
see
appendix
one
follow
advers
featur
breath
difficulti
b
sever
earach
c
vomit
hour
drowsi
part
clinic
manag
adult
refer
hospit
section
sever
assess
adult
refer
hospit
sever
assess
strategi
recommend
patient
refer
hospit
influenzarel
pneumonia
valid
sever
assess
tool
develop
specif
influenzarel
pneumonia
sever
assess
tool
describ
bt
cap
guidelin
recommend
stratif
hospitalis
patient
influenzarel
pneumonia
diseas
sever
group
tabl
addit
presenc
diffus
bilater
lung
infiltr
chest
radiographi
consist
primari
viral
pneumonia
advers
prognost
featur
patient
treat
sever
pneumonia
instanc
clinic
judgement
essenti
assess
diseas
sever
patient
bilater
lung
infiltr
chest
radiographi
consist
primari
viral
pneumonia
manag
sever
pneumonia
regardless
score
hospit
patient
influenzarel
pneumonia
score
high
risk
death
manag
sever
pneumonia
patient
score
increas
risk
death
consid
short
stay
inpati
treatment
hospitalsupervis
outpati
treatment
decis
matter
clinic
judgement
patient
score
low
risk
death
treat
nonsever
pneumonia
may
suitabl
home
treatment
transfer
high
depend
unit
hdu
intens
care
unit
icu
consid
indic
transfer
hdu
icu
differ
patient
influenza
infect
compar
patient
patient
might
requir
hduicu
care
influenzarel
pneumonia
sever
exacerb
underli
comorbid
ill
eg
exacerb
copd
pandem
situat
hduicu
bed
may
readili
avail
prioritis
patient
individu
basi
match
avail
resourc
expect
patient
primari
viral
pneumonia
score
consid
hduicu
transfer
gener
indic
hduicu
transfer
includ
persist
hypoxia
pao
kpa
despit
maxim
oxygen
administr
progress
hypercapnia
sever
acidosi
ph
septic
shock
patient
influenza
admit
intens
care
unit
manag
specialist
appropri
train
intens
care
respiratori
medicin
andor
infecti
diseas
acut
uncompl
influenza
chest
xray
usual
normal
primari
viral
pneumonia
occur
complic
particularli
elderli
adult
chest
xray
often
show
multipl
infiltr
consolid
cavit
pleural
chang
suggest
bacteri
superinfect
combin
viralbacteri
pneumonia
clinic
featur
typic
appear
later
primari
viral
pneumonia
chest
xray
often
show
cavit
pleural
effus
secondari
bacteri
pneumonia
usual
occur
appar
improv
viral
infect
chest
xray
may
show
consolid
chest
xray
obtain
assess
suspect
case
influenza
seen
hospit
set
accid
emerg
depart
acut
admiss
ward
patient
subsequ
follow
hospit
outpati
clinic
gener
practition
repeat
chest
xray
obtain
around
six
week
respiratori
symptom
sign
persist
higher
risk
underli
malign
especi
smoker
year
age
investig
includ
ct
thorac
scan
bronchoscopi
consid
chest
xray
remain
abnorm
follow
patient
ill
sever
enough
present
secondari
care
follow
test
may
use
full
blood
count
leucocytosi
left
shift
may
occur
primari
viral
pneumonia
mix
viralbacteri
pneumonia
secondari
bacteri
pneumonia
lymphopenia
note
human
case
sever
avian
influenza
urea
electrolyt
may
reveal
evid
hypo
hypernatraemia
renal
impair
liver
function
test
usual
normal
creatin
kinas
ck
may
elev
sever
myalgia
creactiv
protein
crp
unlik
help
except
superimpos
bacteri
infect
suspect
howev
diagnost
valu
crp
lower
respiratori
tract
infect
remain
controversi
follow
blood
test
obtain
patient
admit
hospit
full
blood
count
urea
creatinin
electrolyt
liver
function
test
creatin
kinas
myositi
suspect
patient
suspect
secondari
bacteri
infect
creactiv
protein
crp
level
may
aid
diagnosi
acut
uncompl
influenza
larger
airway
function
remain
normal
howev
often
increas
bronchial
reactiv
may
persist
mani
week
resolut
infect
lung
function
test
unnecessari
patient
section
microbiolog
investig
adult
hospit
introduct
guidelin
provid
base
assumpt
case
first
occur
uk
part
global
pandem
possibl
perform
full
microbiolog
investig
new
case
influenzalik
ill
influenzarel
pneumonia
case
number
rise
possibl
pandem
level
full
inde
microbiolog
investig
becom
increasingli
difficult
thu
data
rel
frequenc
differ
bacteri
caus
influenzarel
pneumonia
antimicrobi
suscept
amongst
investig
case
gather
earlier
pandem
avail
guid
refin
empir
antimicrobi
therapi
choic
case
occur
later
pandem
like
pathogen
implic
influenzarel
pneumonia
streptococcu
pneumonia
staphylococcu
aureu
haemophilu
influenza
lesser
extent
bhaemolyt
streptococci
see
section
earli
phase
uk
alert
level
see
appendix
pandem
microbiolog
diagnost
approach
focu
confirm
influenza
primari
ill
defin
bacteri
caus
influenzarel
pneumonia
optim
specif
individu
patient
gener
popul
antimicrobi
treatment
recommend
later
pandem
phase
uk
alert
level
much
higher
caseload
anticip
microbiolog
investig
focus
patient
sever
influenzarel
pneumonia
unrespons
empir
antimicrobi
therapi
actual
practic
local
level
transit
less
intens
microbiolog
investig
may
occur
uk
alert
level
region
number
local
case
like
vari
region
microbiolog
investig
adult
hospit
part
clinic
manag
adult
refer
hospit
pandem
flu
clinic
manag
patient
influenzalik
ill
influenza
pandem
necessari
perform
full
microbiolog
investig
hospitalis
case
includ
patient
sever
nonsever
influenzarel
pneumonia
order
confirm
influenza
primari
infect
optim
treatment
option
patient
investig
defin
common
bacteri
caus
influenzarel
pneumonia
antimicrobi
suscept
pattern
latter
data
help
inform
empir
antimicrobi
therapi
subsequ
case
microbiolog
investig
may
undertaken
fulli
influenza
rapid
virolog
test
viral
cultur
pcr
respiratori
sampl
yield
posit
result
one
seven
day
ill
onset
howev
present
seven
day
onset
influenzalik
ill
sampl
test
unhelp
instead
serum
sampl
serolog
test
evid
recent
influenza
infect
recommend
specif
detail
microbiolog
guidanc
take
handl
specimen
individu
risk
avian
influenza
prepar
prof
maria
zambon
health
protect
agenc
hpa
centr
infect
avail
wwwhpaorgukinfectionstopicsazavianinfluenza
guidancemicrobiologicalguidancehtm
bacteriolog
investig
recommend
patient
influenzarel
pneumonia
legionella
pneumophila
infect
normal
associ
influenzarel
pneumonia
despit
legionella
urin
antigen
test
perform
sever
cap
case
earli
stage
outbreakincid
order
confirm
legionella
infect
reason
local
increas
pneumonia
admiss
recommend
modifi
contain
british
thorac
societi
commun
acquir
pneumonia
bt
cap
guidelin
thorax
suppl
iv
see
section
pp
updat
see
page
avail
wwwbritthoracicorguk
iqsbt
guidelinespneumoniahtml
sputum
investig
effort
must
focus
qualiti
sampl
ie
patient
abl
expector
purul
sampl
receiv
prior
antibiot
treatment
dissip
larg
number
poor
qualiti
sampl
import
acknowledg
criteria
qualiti
sampl
may
met
minor
admiss
laboratori
offer
reliabl
sputum
gram
stain
appropri
sampl
occas
give
immedi
indic
like
pathogen
like
influenzarel
pneumonia
pathogen
pneumonia
staph
aureu
h
influenza
may
present
characterist
appear
gram
stain
purul
sputum
laboratori
perform
sputum
gram
stain
adher
strict
local
agre
criteria
interpret
report
result
virolog
patient
nose
throat
swab
viru
transport
medium
collect
patient
submit
local
laboratori
relev
laboratori
notifi
suspect
diagnosi
close
liaison
sampl
collect
handl
transport
rapid
test
direct
immunofluoresc
rapid
eia
test
viru
cultur
andor
pcr
undertaken
accord
local
avail
andor
refer
appropri
laboratori
uk
alert
level
uk
high
alert
first
case
pandem
influenza
suspect
case
like
investig
local
health
protect
team
health
protect
agenc
partner
organis
devolv
administr
uk
alert
level
clinician
deal
suspect
case
pandem
influenza
ensur
local
health
protect
team
inform
involv
outset
health
protect
agenc
partner
organis
devolv
administr
establish
network
laboratori
across
uk
profici
test
molecular
diagnosi
influenza
access
servic
via
local
health
protect
team
present
seven
day
onset
ill
acut
serum
ml
clot
blood
collect
convalesc
sampl
ml
clot
blood
obtain
interv
less
seven
day
two
sera
examin
serolog
evid
recent
influenza
infect
b
bacteriolog
patient
influenzarel
pneumonia
follow
bacteriolog
test
perform
blood
cultur
prefer
antibiot
treatment
commenc
pneumococc
urin
antigen
ml
urin
sampl
agent
acut
serum
collect
convalesc
sampl
obtain
interv
less
seven
day
ml
clot
blood
two
sera
store
subsequ
test
pandem
establish
virolog
investig
recommend
routin
pandem
situat
may
readili
avail
diagnosi
influenza
base
clinic
find
influenzarel
pneumonia
present
degre
microbiolog
investig
direct
diseas
sever
presenc
comorbid
influenzarel
pneumonia
examin
sputum
consid
patient
respond
empir
antibiot
therapi
particularli
relev
staph
aureu
identifi
common
influenzarel
pneumonia
pathogen
earli
phase
pandem
contrast
pneumonia
h
influenza
antimicrobi
suscept
organ
less
predict
empir
choic
specul
virolog
routin
recommend
b
bacteriolog
patient
influenzarel
pneumonia
nonsever
pneumonia
score
sputum
sampl
sent
gram
stain
cultur
antimicrobi
suscept
test
patient
respond
empir
antibiot
therapi
ii
sever
pneumonia
score
specif
investig
includ
blood
cultur
prefer
antibiot
treatment
commenc
pneumococc
urin
antigen
ml
urin
sputum
gram
stain
cultur
antimicrobi
suscept
test
sampl
obtain
patient
abl
expector
purul
sampl
ii
receiv
prior
antibiot
treatment
sputum
specimen
transport
rapidli
laboratori
pair
serolog
examin
influenza
agent
acut
serum
collect
convalesc
sampl
obtain
interv
less
seven
day
ml
clot
blood
two
sera
store
subsequ
test
tracheal
endotrach
aspir
sampl
avail
sent
gram
stain
cultur
antimicrobi
suscept
test
section
gener
manag
adult
admit
hospit
initi
manag
depend
assess
reason
admiss
presenc
complic
impact
influenza
preexist
diseas
psychosoci
factor
instanc
elderli
patient
may
requir
admiss
social
reason
broad
term
like
clinic
reason
admiss
order
frequenc
lower
respiratori
tract
complic
non
pneumon
bacteri
exacerb
chronic
lung
diseas
copd
possibl
mix
viral
infect
secondari
bacteri
pneumonia
mix
bacteri
viral
pneumonia
primari
viral
pneumonia
cardiac
complic
exacerb
preexist
cardiac
diseas
cardiac
failur
andor
arrhythmia
primari
myocard
complic
exacerb
preexist
diseas
diabet
mellitu
neurolog
complic
rhabdomyolysi
sever
sinus
initi
manag
like
usual
involv
respiratori
cardiac
complic
especi
pneumonia
discuss
manag
less
common
primari
influenz
complic
rhabdomyolysi
encephalopathi
cover
influenza
patient
admit
hospit
abnorm
cardiorespiratori
symptom
sign
includ
influenzarel
pneumonia
chest
radiograph
electrocardiogram
oxygen
assess
puls
oximetri
prefer
whilst
breath
air
see
section
sao
arteri
blood
ga
measur
patient
featur
sever
ill
knowledg
inspir
oxygen
concentr
essenti
interpret
blood
ga
measur
clearli
record
blood
ga
result
continu
oxygen
therapi
indic
patient
pao
kpa
hypotens
systol
bp
mmhg
metabol
acidosi
bicarbon
mmoll
respiratori
distress
respiratori
rate
aim
oxygen
therapi
maintain
pao
kpa
sao
unless
complic
sever
chronic
obstruct
pulmonari
diseas
ventilatori
failur
high
concentr
oxygen
greater
indic
safe
use
high
concentr
oxygen
therapi
given
patient
preexist
chronic
obstruct
pulmonari
diseas
gener
manag
adult
admit
hospit
part
clinic
manag
adult
refer
hospit
pandem
flu
clinic
manag
patient
influenzalik
ill
influenza
pandem
may
co
retent
reduc
hypox
drive
increas
ventilationperfus
mismatch
patient
initi
treatment
low
oxygen
concentr
progress
increas
basi
repeat
arteri
blood
ga
measur
aim
keep
sao
without
caus
fall
arteri
ph
line
manag
strategi
recommend
nice
copd
guidelin
noninvas
ventil
niv
may
valu
patient
copd
acut
hypercapn
respiratori
failur
use
niv
patient
respiratori
failur
due
sever
pneumonia
without
coexist
copd
shown
influenc
mortal
nevertheless
influenza
pandem
critic
care
level
bed
high
demand
niv
may
valu
bridg
invas
ventil
specif
circumst
instanc
risk
infect
due
dissemin
respiratori
droplet
relat
use
niv
must
taken
account
decid
manag
strategi
respiratori
andor
critic
care
unit
experienc
use
niv
best
place
ensur
appropri
infect
control
measur
adopt
observ
time
includ
use
person
protect
equip
ppe
see
uk
infect
control
guidanc
pandem
influenza
patient
assess
volum
deplet
may
requir
iv
fluid
potenti
influenza
caus
cardiac
decompens
either
exacerb
preexist
cardiac
diseas
primari
myocard
born
mind
complic
heart
failur
arrhythmia
manag
usual
way
physiotherapi
may
benefit
select
patient
excess
bronchial
secret
particularli
concurr
chronic
obstruct
pulmonari
diseas
case
sever
ill
requir
prolong
hospit
admiss
increas
nutrit
support
whether
enter
parenter
via
nasogastr
feed
arrang
hypox
patient
receiv
appropri
oxygen
therapi
monitor
oxygen
satur
inspir
oxygen
concentr
aim
maintain
pao
kpa
sao
high
concentr
oxygen
safe
given
uncompl
pneumonia
oxygen
therapi
patient
preexist
copd
complic
ventilatori
failur
guid
repeat
arteri
blood
ga
measur
noninvas
ventil
may
help
patient
without
preexist
copd
develop
respiratori
failur
niv
may
valu
bridg
invas
ventil
specif
circumst
critic
care
level
bed
high
demand
respiratori
andor
critic
care
unit
experienc
use
niv
best
place
ensur
appropri
infect
control
measur
adopt
time
patient
assess
cardiac
complic
also
volum
deplet
need
addit
intraven
fluid
nutrit
support
given
sever
prolong
ill
monitor
conduct
hospit
stay
puls
blood
pressur
respiratori
rate
temperatur
oxygen
satur
record
inspir
oxygen
concentr
time
mental
statu
measur
initi
least
twice
daili
conveni
perform
use
earli
warn
score
ew
chart
ward
staff
familiar
sever
ill
requir
continu
oxygen
cardiovascular
support
monitor
frequent
failur
improv
clinic
within
hour
result
full
clinic
reassess
failur
improv
day
indic
repeat
chest
radiograph
temperatur
respiratori
rate
puls
blood
pressur
mental
statu
oxygen
satur
inspir
oxygen
concentr
monitor
record
initi
least
twice
daili
frequent
sever
ill
requir
regular
oxygen
therapi
earli
warn
score
system
conveni
way
perform
addit
full
clinic
reassess
chest
radiograph
repeat
patient
progress
satisfactorili
consider
pressur
discharg
patient
earli
pandem
type
avail
outofhospit
facil
dictat
hospit
discharg
decis
guidanc
regard
simpl
paramet
review
consid
hospit
discharg
obtain
recent
us
prospect
multicentr
observ
cohort
studi
patient
admit
hospit
cap
offer
advic
patient
admit
influenzarel
respiratori
complic
patient
review
hour
discharg
home
two
follow
unstabl
clinic
factor
consid
continu
hospit
manag
temperatur
heart
rate
respiratori
rate
systol
blood
pressur
mmhg
oxygen
satur
inabl
maintain
oral
intak
usual
practic
arrang
routin
hospit
clinic
follow
repeat
chest
radiograph
around
six
week
discharg
acut
respiratori
ill
pneumonia
howev
evid
base
recommend
regard
valu
practic
patient
otherwis
recov
satisfactorili
also
known
whether
valu
arrang
clinic
follow
hospit
clinic
rather
patient
gener
practition
influenza
pandem
situat
like
patient
develop
complic
signific
worsen
underli
diseas
offer
clinic
review
one
venu
discharg
patient
offer
access
inform
takehom
medic
smoke
lifestyl
advic
appropri
potenti
futur
complic
action
take
event
relaps
symptom
followup
clinic
review
consid
patient
suffer
signific
complic
signific
worsen
underli
diseas
either
gener
practition
hospit
clinic
discharg
follow
patient
offer
access
inform
ill
takehom
medic
followup
arrang
respons
hospit
team
arrang
followup
plan
patient
gener
practition
section
use
antivir
hospitalis
adult
drug
use
antivir
treatment
pandem
oseltamivir
neuraminidas
inhibitor
mainstay
therapi
pandem
inhibitor
amantadin
rimantadin
unsuit
use
treatment
due
rapid
emerg
resist
togeth
sideeffect
clinic
trial
data
accru
date
base
season
interpandem
influenza
anticip
posit
effect
antivir
pandem
reduct
ill
durat
hour
therefor
rapid
mobilis
affect
individu
includ
essenti
worker
b
possibl
reduct
hospitalis
infect
individu
c
reduct
subsequ
antibiot
use
infect
individu
insuffici
evid
accru
date
determin
effect
antivir
overal
mortal
therefor
major
util
antivir
maintain
essenti
workforc
reduc
hospitalis
antibiot
treatment
complic
neuraminidas
inhibitor
pandem
individu
consid
treatment
neuraminidas
inhibitor
follow
acut
influenzalik
ill
fever
symptomat
two
day
less
treatment
schedul
adult
oseltamivir
mg
everi
hour
day
dose
reduc
creatinin
clearanc
less
mlminut
except
patient
unabl
mount
adequ
febril
respons
eg
immunocompromis
elderli
make
still
elig
despit
lack
document
fever
ii
hospitalis
patient
sever
ill
particularli
also
immunocompromis
may
benefit
antivir
treatment
start
hour
diseas
onset
advic
reflect
lack
robust
evid
guid
use
antivir
except
circumst
place
high
valu
potenti
benefit
antivir
therapi
drug
avail
treatment
prevent
infect
influenza
summaris
tabl
four
drug
avail
older
agent
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
older
agent
older
agent
amantadin
rimantadin
rimantadin
current
licens
uk
relat
substanc
act
block
ionchannel
function
influenza
viru
protein
protein
although
minor
surfac
constitu
influenza
viru
particl
essenti
viru
replic
agent
activ
influenza
type
amantadin
recommend
nice
treatment
andor
prophylaxi
interpandem
influenza
absenc
nation
stockpil
suppli
amantadin
expect
low
virus
south
east
asia
resist
amantadin
agent
may
play
role
depend
natur
pandem
strain
two
neuraminidas
inhibitor
far
develop
level
entri
formulari
zanamivir
modif
dehydr
neuramin
acid
deriv
oseltamivir
similar
molecul
except
cyclohexen
ring
replac
polyglycerol
moieti
lipophil
sidechain
oseltamivir
taken
mouth
wherea
zanamivir
must
inhal
use
diskhal
devic
intraven
formul
zanamivir
develop
efficaci
establish
may
relev
manag
ventil
case
drug
activ
influenza
type
well
type
b
virus
older
agent
amantadin
rimantadin
effect
treatment
type
influenza
viru
infect
treatment
begun
within
hour
onset
ill
histor
data
show
shorten
ill
approxim
one
day
efficaci
prevent
complic
hospitalis
death
never
establish
although
drug
effect
use
clinic
influenza
treatment
limit
result
procliv
induc
viral
resist
sideeffect
profil
sever
larg
clinic
trial
demonstr
util
zanamivir
oseltamivir
treatment
adult
influenza
commun
virtual
studi
efficaci
neuraminidas
inhibitor
reduc
complic
conduct
oseltamivir
drug
shown
effect
outcom
time
recoveri
metaanalysi
adult
adolesc
virolog
proven
influenza
ill
oseltamivir
treatment
reduc
overal
antibiot
use
reason
far
neuraminidas
inhibitor
extens
investig
patient
highest
risk
seriou
complic
influenza
patient
includ
elderli
seriou
cardiopulmonari
ill
chronic
obstruct
pulmonari
diseas
neuraminidas
inhibitor
associ
reduct
mortal
clinic
trial
conduct
far
appropri
measur
known
certain
whether
neuraminidas
inhibitor
effect
pandem
influenza
use
assess
interpandem
influenza
virul
moder
degre
host
immun
antivir
activ
like
adequ
vitro
neuraminidas
inhibitor
demonstr
broad
spectrum
activ
multipl
avian
influenza
virus
older
agent
rimantadin
amantadin
studi
hong
kong
pandem
influenza
appear
pandem
efficaci
review
hayden
older
agent
given
four
eight
week
period
prophylaxi
commun
set
protect
efficaci
influenza
ill
averag
compar
placebo
compar
efficaci
observ
agent
studi
interpandem
period
amantadin
rimantadin
use
treat
patient
resist
virus
emerg
rapidli
approxim
treat
children
adult
shed
resist
variant
start
two
five
day
onset
treatment
resist
virus
shed
patient
retain
full
virul
infect
transmiss
potenti
contact
case
treat
amantadin
rimantadin
given
postexposur
prophylaxi
older
agent
reduct
secondari
case
minim
contrast
frequenc
emerg
resist
treatment
neuraminidas
inhibitor
report
low
howev
studi
experiment
induc
influenza
infect
healthi
adult
particip
shed
virus
histidin
tyrosin
substitut
posit
within
bind
site
oseltamivir
case
volunt
increas
influenza
viral
load
within
nasopharynx
deterior
symptom
far
proven
instanc
transmiss
oseltamivir
zanamivirresist
variant
field
clinic
trial
experi
rel
small
current
sequenc
analysi
human
isol
north
vietnam
reveal
viru
resist
sequenc
although
isol
fulli
resist
oseltamivir
shift
upward
therefor
less
suscept
oseltamivir
isol
test
region
patient
viru
isol
concurr
treat
oseltamivir
amantadin
rimantadin
caus
nausea
vomit
small
percentag
individu
receiv
tabl
unfortun
amantadin
also
associ
unpleas
central
nervou
system
sideeffect
includ
anxieti
depress
insomnia
hallucin
sideeffect
doserel
resolv
discontinu
drug
case
neuraminidas
inhibitor
drug
appear
rel
safe
zanamivir
sideeffect
result
bronchospasm
might
potenti
seriou
patient
asthma
oseltamivir
requir
dosereduct
patient
low
creatinin
clearanc
mlmin
nausea
occur
oseltamivir
recipi
seldom
sever
enough
lead
drug
discontinu
see
tabl
antimicrobi
chemotherapi
indic
primarili
respiratori
complic
due
secondari
bacteri
infect
princip
influenzarel
pneumonia
major
patient
exacerb
chronic
obstruct
pulmonari
diseas
copd
chronic
lung
condit
due
secondari
bacteri
infect
bronchiectasi
also
requir
antimicrobi
chemotherapi
patient
sever
sinus
pneumonia
lower
respiratori
tract
infect
defin
microbiolog
initi
assess
henc
prescrib
empir
broad
term
antimicrobi
manag
patient
follow
guidanc
offer
relev
nation
guidelin
manag
communityacquir
pneumonia
copd
modifi
light
differ
rang
pathogen
bacteria
may
implic
specif
staph
aureu
infect
minor
case
aetiolog
may
determin
hospit
admiss
therebi
permit
modif
initi
empir
regimen
although
pathogen
respons
communityacquir
pneumonia
divers
case
bacteri
pneumonia
complic
influenza
princip
pathogen
cover
initi
empir
antimicrobi
therapi
includ
pneumonia
h
influenza
staph
aureu
latter
said
common
combin
viral
bacteri
pneumonia
strain
staphylococci
synergist
effect
viru
gramneg
enter
bacillari
infect
also
sometim
seen
exacerb
copd
larg
associ
pneumonia
h
influenza
moraxella
catarrhali
sever
assess
associ
preexist
comorbid
diseas
essenti
predict
prognosi
turn
determin
manag
choic
antibiot
therapi
method
administr
see
section
influenza
pandem
princip
relat
concern
local
pattern
antimicrobi
resist
staph
aureu
assess
possibl
methicillinresist
aureu
mrsa
present
local
clinician
kept
close
inform
local
shift
antimicrobi
resist
pattern
start
pandem
staphylococcu
aureu
wide
resist
penicillin
increas
number
methicillinresist
mrsa
occur
commun
gener
reflect
hospitalis
within
recent
past
resid
within
nurs
home
henc
blactamas
unstabl
penicillin
penicillin
g
aminopenicillin
case
mrsa
isoxazolyl
penicillin
flucloxacillin
cloxacillin
cephalosporin
inappropri
infect
true
incid
resist
among
pathogen
commun
difficult
estim
sinc
laboratori
sampl
come
select
popul
limit
mind
presenc
blactamas
product
among
h
influenza
vari
geograph
rang
variou
part
uk
catarrhali
high
rate
blactamas
product
antibiot
resist
among
pneumonia
concern
world
wide
owe
domin
organ
caus
communityacquir
pneumonia
penicillin
macrolid
resist
frequent
link
howev
date
common
enough
problem
uk
influenc
initi
antimicrobi
manag
decis
recent
data
provid
hpa
antimicrobi
sensit
respiratori
pathogen
isol
blood
respiratori
sampl
last
three
four
year
robert
georg
person
commun
found
macrolid
resist
amongst
methicillinsensit
staphylococcu
aureu
mssa
isol
pneumonia
macrolid
apart
clarithromycin
poor
vivo
activ
h
influenza
contrast
tetracyclin
resist
around
pneumonia
h
influenza
mssa
fluoroquinolon
activ
methicillinsensit
staphylococcu
aureu
mssa
mic
figur
mgl
ciprofloxacin
mgl
levofloxacin
mgl
moxifloxacin
modern
fluoroquinolon
oral
moxifloxacin
oral
iv
levofloxacin
current
licens
uk
therefor
possibl
choic
secondari
bacteri
infect
follow
influenza
mssa
like
pathogen
recent
pharmacokinet
pharmacodynam
vitro
studi
indic
moxifloxacin
mg
od
advantag
ciprofloxacin
mg
bd
levofloxacin
mg
od
antimicrobi
effect
staph
aureu
quinolon
levofloxacin
moxifloxacin
also
provid
cover
pneumonia
h
influenza
mrsa
unlik
pathogen
uk
context
communityacquir
respiratori
bacteri
infect
follow
influenza
fluoroquinolon
suffici
activ
mrsa
robust
research
studi
avail
provid
evidencebas
guidanc
best
empir
choic
antimicrobi
therapi
bacteri
complic
influenza
reason
recommend
treatment
made
basi
assess
matrix
laboratori
clinic
pharmacokinet
safeti
data
interpret
inform
manner
take
account
publish
guidelin
chronic
lung
diseas
particularli
copd
bacteri
exacerb
commonest
caus
admiss
like
patient
suffici
ill
requir
hospit
admiss
exacerb
requir
antibiot
manag
underli
macrolid
erythromycin
mg
qd
po
clarithromycin
mg
bd
b
po
fluoroquinolon
enhanc
pneumococc
activ
eg
levofloxacin
mg
od
po
moxifloxacin
mg
od
po
c
iv
need
coamoxiclav
g
td
iv
cefuroxim
g
td
iv
cefotaxim
g
td
iv
macrolid
erythromycin
mg
qd
iv
clarithromycin
mg
bd
b
iv
levofloxacin
mg
od
iv
c
hospitaltr
sever
pneumonia
coamoxiclav
g
td
iv
cefuroxim
g
td
iv
cefotaxim
g
td
iv
plu
macrolid
erythromycin
mg
qd
iv
clarithromycin
mg
bd
b
iv
fluoroquinolon
enhanc
pneumococc
activ
eg
levofloxacin
mg
bd
iv
po
c
plu
either
macrolid
erythromycin
mg
qd
iv
clarithromycin
mg
bd
b
iv
blactamas
stabl
antibiot
coamoxiclav
g
td
iv
cefuroxim
g
td
iv
cefotaxim
g
td
iv
altern
regimen
provid
intoler
hypersensit
prefer
regimen
b
clarithromycin
may
substitut
gastrointestin
intoler
oral
erythromycin
also
benefit
twice
daili
dosag
better
cover
h
influenza
c
levofloxacin
moxifloxacin
current
uklicens
fluoroquinolon
enhanc
activ
pneumonia
addit
cover
staph
aureu
levofloxacin
come
oral
parenter
formul
licens
sever
pneumonia
moxifloxacin
come
oral
formul
uk
licens
sever
pneumonia
futur
fluoroquinolon
gemifloxacin
gatifloxacin
like
extend
choic
licens
uk
abbrevi
od
daili
bd
twice
td
time
qd
time
iv
intraven
po
oral
switch
parenter
drug
equival
oral
prepar
made
soon
clinic
appropri
absenc
microbiolog
confirm
infect
case
parenter
cephalosporin
oral
switch
coamoxiclav
mg
td
recommend
rather
oral
cephalosporin
condit
copd
follow
standard
guidelin
includ
use
corticosteroid
indic
antibiot
cover
like
bacteri
pathogen
includ
pneumonia
h
influenza
catarrhali
staph
aureu
oral
therapi
suffici
without
advers
sever
featur
abl
take
oral
medic
prefer
first
choic
antibiot
nonpneumon
bronchial
infect
includ
effect
oral
blactamas
stabl
agent
coamoxiclav
tetracyclin
doxycyclin
macrolid
altern
intoler
prefer
first
choic
whilst
rememb
possibl
antimicrobi
resist
clarithromycin
better
activ
h
influenza
azithromycin
newergener
fluroquinolon
eg
levofloxacin
moxifloxacin
enhanc
activ
pneumonia
altern
choic
increas
likelihood
resist
local
issu
dictat
choic
previous
well
adult
acut
bronchiti
complic
influenza
absenc
pneumonia
routin
requir
antibiot
antibiot
consid
previous
well
adult
develop
worsen
symptom
recrudesc
fever
increas
dyspnoea
patient
high
risk
complic
secondari
infect
appendix
consid
antibiot
presenc
lower
respiratori
featur
patient
adequ
treat
oral
antibiot
prefer
choic
includ
coamoxiclav
tetracyclin
macrolid
clarithromycin
erythromycin
fluoroquinolon
activ
pneumonia
staph
aureu
altern
choic
certain
circumst
patient
suffer
primari
viral
pneumonia
combin
viral
bacteri
pneumonia
secondari
bacteri
pneumonia
featur
cover
section
patient
pneumon
involv
receiv
antibiot
principl
antibiot
select
nonsever
influenzarel
pneumonia
similar
manag
sporad
communityacquir
pneumonia
gener
except
adequ
cover
staph
aureu
includ
empir
regimen
also
felt
necessari
routin
provid
cover
atyp
pathogen
mycoplasma
pneumonia
chlamydia
sp
coxiella
burnetti
legionella
sp
pandem
larg
major
patient
hospitalis
direct
result
influenza
complic
caus
bacteri
infect
reason
oral
coamoxiclav
tetracyclin
doxycyclin
prefer
regimen
tabl
oral
therapi
inappropri
parenter
coamoxiclav
secondor
thirdgener
cephalosporin
offer
altern
base
invitro
data
activ
select
cephalosporin
mssa
uk
descend
rank
order
cefuroxim
mgl
cefotaxim
mgl
ceftriaxon
mgl
robert
georg
person
commun
cefuroxim
cefotaxim
recommend
cephalosporin
offer
adequ
mssa
cover
within
empir
regimen
macrolid
one
new
fluoroquinolon
identifi
altern
hospitalis
patient
specif
circumst
includ
intoler
penicillin
local
microbiolog
surveil
suggest
better
choic
time
complet
guidelin
levofloxacin
moxifloxacin
licens
avail
uk
pneumonia
flucloxacillin
recommend
part
empir
regimen
activ
narrow
spectrum
pathogen
predominantli
staph
aureu
would
requir
use
combin
one
antibiot
offer
antibiot
choic
confirm
methicillinsensit
staph
aureu
mssa
infect
regardless
regimen
select
critic
antibiot
administ
promptli
within
four
hour
admiss
case
patient
sever
pneumonia
without
delay
admit
doctor
admiss
ward
gener
practition
delay
expect
hospit
admiss
process
delay
administr
antibiot
relat
advers
mortal
studi
particularli
manag
elderli
patient
follow
initi
assess
empir
therapi
progress
monitor
care
rout
choic
antibiot
treatment
requir
adjust
either
step
broaden
spectrum
microbiolog
activ
light
clinic
deterior
result
posit
microbiolog
inform
step
improv
discuss
patient
adequ
treat
oral
antibiot
oral
therapi
coamoxiclav
tetracyclin
prefer
oral
therapi
contraind
recommend
parenter
choic
includ
intraven
coamoxiclav
second
third
gener
cephalosporin
cefuroxim
cefotaxim
respect
macrolid
erythromycin
clarithromycin
fluoroquinolon
activ
pneumonia
staph
aureu
altern
regimen
intoler
penicillin
current
levofloxacin
moxifloxacin
recommend
fluoroquinolon
licens
uk
antibiot
administ
within
four
hour
admiss
mortal
greatli
increas
sever
pneumonia
section
ill
may
progress
microbiolog
inform
avail
prefer
altern
initi
treatment
regimen
summaris
tabl
recommend
broadspectrum
blactam
regimen
plu
macrolid
sever
influenzarel
pneumonia
base
follow
rational
pneumonia
staph
aureu
remain
predomin
pathogen
gramneg
enter
bacilli
although
uncommon
carri
high
mortal
b
recommend
empir
regimen
offer
doubl
cover
like
pathogen
implic
influenzarel
pneumonia
evid
indic
combin
therapi
associ
better
outcom
sever
pneumonia
c
although
evid
increas
incid
infect
atyp
pathogen
influenzarel
pneumonia
sever
pneumonia
felt
necessari
includ
cover
atyp
pathogen
particularli
legionella
sp
may
possibl
outset
distinguish
patient
sporad
sever
communityacquir
pneumonia
legionella
infect
import
influenzarel
pneumonia
parenter
administr
antibiot
recommend
sever
communityacquir
pneumonia
regardless
patient
abil
otherwis
take
oral
medic
ensur
prompt
high
blood
lung
concentr
antibiot
fluoroquinolon
offer
altern
despit
limit
data
use
sever
pneumonia
time
write
levofloxacin
licens
avail
agent
uk
sever
pneumonia
market
parenter
oral
formul
howev
clinic
experi
avail
recommend
combin
anoth
agent
activ
pneumonia
staph
aureu
broadspectrum
blactam
macrolid
manag
sever
influenzarel
pneumonia
patient
sever
pneumonia
treat
immedi
diagnosi
parenter
antibiot
intraven
combin
broadspectrum
blactamas
stabl
antibiot
coamoxiclav
second
eg
cefuroxim
third
eg
cefotaxim
gener
cephalosporin
togeth
macrolid
clarithromycin
erythromycin
prefer
altern
regimen
includ
fluoroquinolon
enhanc
activ
pneumococci
togeth
broadspectrum
blactamas
stabl
antibiot
macrolid
current
levofloxacin
fluoroquinolon
licenc
uk
patient
hospit
within
last
month
higher
chanc
carri
mrsa
oppos
patient
hospitalis
recent
therefor
due
consider
given
possibl
mrsa
known
suspect
staphylococc
pneumonia
andor
respond
empir
therapi
iv
rout
chang
oral
rigid
recommend
concern
time
transfer
oral
therapi
studi
area
need
decis
must
individualis
basi
assess
factor
includ
absenc
contraind
oral
administr
avail
microbiolog
inform
regard
aetiolog
infect
clear
evid
patient
respond
initi
therapi
recommend
guidelin
oral
therapi
consid
patient
shown
clear
evid
improv
whose
temperatur
resolv
period
hour
patient
treat
initi
parenter
antibiot
transfer
oral
regimen
soon
clinic
improv
occur
temperatur
normal
hour
provid
contraind
oral
rout
long
antibiot
given
precis
method
reliabl
identifi
microbiolog
clinic
endpoint
durat
therapi
remain
subject
clinic
judgement
custom
reason
durat
therapi
vari
individu
patient
diseas
sever
speed
resolut
patient
admit
hospit
nonsever
uncompl
pneumonia
seven
day
appropri
antibiot
recommend
sever
microbiolog
undefin
pneumonia
ten
day
treatment
propos
extend
day
aureu
gramneg
enter
bacilli
pneumonia
suspect
confirm
failur
initi
empir
therapi
patient
fail
respond
initi
empir
therapi
sever
possibl
need
consid
first
whether
correct
diagnosi
made
radiograph
review
recommend
communityand
hospitalmanag
patient
may
also
indic
complic
pneumonia
pleural
effusionempyema
lung
abscess
worsen
pneumon
shadow
common
presenc
staphylococc
infect
initi
empir
antibiot
regimen
may
need
reassess
howev
complianc
adequ
absorpt
oral
regimen
first
consid
microbiolog
data
review
specimen
examin
view
exclud
staph
aureu
gramneg
bacillari
infect
hospitalmanag
nonsever
ill
patient
chang
new
fluoroquinolon
levofloxacin
provid
second
altern
sever
ill
patient
alreadi
receiv
blactam
clarithromycin
regimen
recommend
staphylococc
cover
ad
includ
cover
mrsa
addit
urgent
referr
respiratori
physician
made
clinic
assess
includ
possibl
need
bronchoscop
sampl
rapid
mrsa
diagnost
techniqu
evalu
stage
nonsever
pneumonia
hospit
combin
therapi
chang
fluoroquinolon
effect
pneumococc
staphylococc
cover
option
ad
antibiot
effect
mrsa
option
sever
pneumonia
respond
combin
antibiot
therapi
specif
pathogendirect
antibiot
therapi
optimum
antibiot
choic
specif
pathogen
identifi
pathogen
identifi
specif
therapi
summaris
tabl
propos
transfer
patient
empir
pathogentarget
therapi
regimen
rout
administr
determin
continu
need
parenter
therapi
known
drug
intoler
recommend
base
synthesi
inform
includ
vitro
activ
drug
appropri
pharmacokinet
clinic
evid
efficaci
glean
varieti
studi
choic
agent
may
modifi
follow
avail
sensit
test
follow
consult
specialist
microbiolog
infecti
diseas
respiratori
medicin
close
liaison
local
microbiolog
servic
essenti
pandem
current
pneumonia
highli
resist
penicillin
mic
mgl
uncommon
uk
howev
import
situat
monitor
futur
use
antibiot
hospitalis
adult
part
clinic
manag
adult
refer
hospit
pandem
flu
clinic
manag
patient
influenzalik
ill
influenza
pandem
either
ciprofloxacin
mg
bd
iv
piperacillin
g
td
iv
gentamicin
tobramycin
dose
monitor
higher
dose
penicillin
altern
regimen
may
need
consid
staphylooccu
aureu
uncommon
caus
sporad
communityacquir
pneumonia
uk
assum
much
greater
potenti
import
pandem
commun
isol
methicillinsensit
although
recent
increas
mrsa
hospitalis
patient
may
result
subsequ
readmiss
mrsa
infect
secondari
influenza
option
methicillinsensit
resist
infect
base
parenter
administr
view
seriou
natur
staphylococc
pneumonia
specif
pathogen
identifi
antibiot
recommend
summaris
children
high
fever
cough
influenzalik
symptom
seen
commun
health
profession
nurs
doctor
seven
year
age
featur
put
high
risk
complic
treat
oseltamivir
given
advic
antipyret
fluid
children
one
year
age
risk
complic
appendix
seen
gp
children
may
consid
increas
risk
complic
cough
fever
influenzalik
ill
temperatur
either
chronic
comorbid
diseas
see
appendix
ii
one
follow
featur
breath
difficulti
sever
earach
vomit
hour
drowsi
patient
offer
antibiot
well
oseltamivir
one
year
age
advic
antipyret
fluid
children
one
year
age
none
featur
treat
antipyret
fluid
low
threshold
antibiot
becom
unwel
sever
ill
children
refer
assess
admiss
pandem
situat
paediatr
high
depend
intens
care
bed
like
fill
quickli
insuffici
meet
demand
children
triag
senior
paediatrician
duti
consult
tertiari
specialist
respiratori
medicin
paediatr
intens
care
paediatr
infecti
diseas
triag
basi
sever
child
acut
b
coexist
diseas
likelihood
child
achiev
full
recoveri
admiss
possibl
gener
investig
children
hospit
part
clinic
manag
children
refer
hospit
pandem
flu
clinic
manag
patient
influenzalik
ill
influenza
pandem
tertiari
specialist
provid
advic
support
manag
gener
paediatrician
case
report
vietnam
seven
children
wbc
mean
lymphopenia
mean
six
seven
children
die
contrast
two
seven
children
report
hong
kong
die
leukopen
lymphopen
survivor
mean
wbc
lymphocyt
count
four
five
case
report
thailand
lymphopen
influenza
thrombocytopenia
found
thrombocytopenia
found
four
seven
case
infect
vietnames
children
liver
transaminas
rais
influenza
patient
rais
six
six
measur
hong
kong
outbreak
five
six
measur
vietnam
creactiv
protein
crp
unhelp
influenza
valu
ratio
invert
two
children
three
adult
measur
vietnam
outbreak
mean
rang
two
patient
surviv
full
blood
count
differenti
urea
creatinin
electrolyt
liver
enzym
blood
cultur
done
sever
ill
children
one
largest
studi
valu
chest
radiographi
undertaken
children
age
two
month
five
year
communityacquir
pneumonia
manag
outpati
time
recoveri
main
outcom
chest
radiographi
affect
clinic
outcom
children
acut
lower
respiratori
infect
lack
effect
independ
clinician
experi
clinic
identifi
subgroup
children
within
case
definit
pneumonia
like
benefit
chest
radiograph
author
conclud
routin
use
chest
radiographi
benefici
ambulatori
children
age
two
month
acut
lower
respiratori
tract
infect
lrti
clinician
base
diagnosi
lower
respiratori
infect
young
infant
radiograph
diagnosi
awar
variat
intraobserv
interobserv
agreement
among
radiologist
radiograph
featur
use
diagnosi
also
variat
specif
radiolog
featur
use
interpret
radiograph
recent
studi
standard
cxr
interpret
paediatr
pneumonia
illustr
import
standardis
train
cardin
find
consolid
diagnosi
pneumonia
appear
highli
reliabl
reason
specif
bacteri
pneumonia
patient
alveolar
shadow
bacteri
proven
pneumonia
overal
chest
radiographi
insensit
use
differenti
patient
bacteri
pneumonia
whose
pneumonia
nonbacteri
context
influenza
pandem
cxr
distinguish
viral
pneumonia
viral
ill
bacteri
superinfect
children
sign
pneumonia
treat
antibiot
cxr
perform
children
hypox
sever
ill
deterior
despit
treatment
oxygen
satur
sao
measur
provid
noninvas
estim
arteri
oxygen
puls
oximetri
key
tool
assess
manag
essenti
use
correctli
user
awar
possibl
artefactu
low
read
oximet
appear
easi
use
requir
calibr
howev
requir
pulsatil
signal
patient
also
highli
subject
motion
artefact
obtain
reliabl
read
child
still
quiet
use
paediatr
wrap
around
probe
emit
receiv
diod
need
care
oppos
good
puls
signal
plethysmograph
obtain
signal
obtain
satur
read
watch
least
second
valu
record
adequ
stabl
trace
obtain
puls
oximetri
perform
everi
child
assess
admiss
hospit
pneumonia
read
conjunct
correspond
section
adult
section
part
adult
extent
virolog
microbiolog
investig
undertaken
children
vari
accord
stage
pandem
addit
accord
sever
individu
case
note
howev
clinic
featur
influenza
children
less
characterist
adult
see
section
need
special
diagnost
test
therefor
greater
util
rapid
influenza
test
demonstr
studi
rapid
knowledg
diagnosi
influenza
within
ten
minut
shown
impact
clinician
behaviour
respect
antibiot
use
perform
test
admiss
hospit
may
imagin
pandem
situat
test
could
result
earlier
use
antivir
therapi
ration
approach
hospit
admiss
prophylaxi
contact
howev
use
molecular
refer
standard
one
test
shown
low
sensit
high
specif
suggest
role
might
better
rule
influenza
rather
rule
similar
conclus
made
commerci
rapid
test
reflect
rapid
antigen
test
posit
two
six
patient
avian
influenza
need
bacteriolog
test
case
influenza
pneumonia
also
logic
rang
pathogen
similar
adult
except
legionella
infect
extrem
unlik
occur
previous
healthi
child
legionellaspecif
antigen
test
therefor
unnecessari
urinari
pneumococc
antigen
test
children
may
lack
sensit
specif
interpret
care
sputum
collect
children
also
unreli
although
older
children
eg
year
age
may
possibl
handl
indic
adult
virolog
children
influenza
pandem
children
like
admit
hospit
sever
diseas
complic
impact
influenza
preexist
disord
cardiac
respiratori
neurolog
diseas
manag
preexist
disord
outsid
guidelin
common
reason
admiss
like
lower
respiratori
tract
diseas
either
viral
bacteri
mix
pneumonia
reason
admiss
includ
sever
gastroenter
cardiac
diseas
viral
myocard
enceph
children
triag
ward
hdupicu
sever
assess
section
influenza
pandem
like
occur
winter
month
winter
virus
respons
paediatr
morbid
hospit
admiss
circul
rsv
adenoviru
particularli
earli
stage
pandem
uk
alert
level
import
use
rapid
virolog
test
attempt
cohort
influenzaposit
rsvposit
infant
separ
separ
patient
see
uk
infect
control
guidanc
pandem
influenza
hypox
infant
children
may
appear
cyanos
agit
may
indic
hypoxia
patient
whose
oxygen
satur
less
breath
air
treat
oxygen
given
nasal
cannula
head
box
face
mask
maintain
oxygen
satur
nasal
cannula
deliv
fio
around
even
flow
rate
lmin
infant
lmin
older
children
altern
method
deliv
higher
concentr
humidifi
oxygen
head
box
venturi
face
mask
may
necessari
sao
maintain
fio
addit
support
cpap
bipap
intub
ventil
consid
patient
whose
oxygen
satur
less
breath
air
treat
oxygen
given
nasal
cannula
head
box
face
mask
maintain
oxygen
satur
children
unabl
maintain
fluid
intak
due
breathless
fatigu
gastroenter
need
fluid
therapi
possibl
addit
fluid
enter
rout
nasogastr
tube
feed
use
smallest
tube
pass
smallest
nostril
minim
effect
respiratori
statu
sever
ill
children
may
need
intraven
fluid
child
oxygen
therapi
intraven
fluid
given
basal
level
avoid
complic
inappropri
adh
secret
serum
electrolyt
monitor
monitor
depend
child
condit
sever
ill
children
need
continu
monitor
heart
rate
respiratori
rate
oxygen
satur
neurolog
statu
children
oxygen
therapi
fourhourli
monitor
includ
oxygen
satur
chest
physiotherapi
benefici
previous
healthi
children
pneumonia
children
underli
condit
cystic
fibrosi
neuromuscular
weak
benefit
intens
physiotherapi
children
influenza
gener
pyrexi
may
pain
includ
headach
chest
pain
arthralgia
abdomin
pain
earach
associ
otiti
media
pleural
pain
may
interfer
depth
breath
may
impair
abil
cough
antipyret
analges
use
keep
child
comfort
help
cough
children
safe
discharg
hospit
pandem
situat
great
pressur
hospit
bed
children
assess
discharg
least
twice
daili
children
remain
hospit
receiv
therapi
could
given
commun
previous
healthi
children
suitabl
discharg
criteria
would
child
clearli
improv
child
physiolog
stabl
child
toler
oral
feed
respiratori
rate
infant
awak
oxygen
satur
air
children
make
unev
recoveri
requir
follow
prolong
ill
may
follow
gener
practition
children
sever
diseas
andor
high
risk
sequela
need
hospit
follow
children
lobar
collaps
followup
cxr
followup
cxr
acut
uncompl
pneumonia
valu
patient
asymptomat
read
conjunct
correspond
section
adult
section
part
five
antivir
agent
theoret
avail
therapi
influenza
children
ion
channel
inhibitor
amantadin
rimantadin
administ
oral
influenza
neuraminidas
inhibitor
oseltamivir
administ
oral
zanamavir
administ
inhal
ribavirin
aerosolis
limit
amantadin
rimantadin
detail
section
particularli
context
pandem
resist
may
alreadi
present
shown
effect
treatment
influenza
children
concern
exist
develop
resist
therapi
agent
household
studi
show
treatment
prophylaxi
rimantadin
result
rapid
select
transmiss
drug
resist
viru
doubleblind
randomis
placebo
control
studi
children
year
age
receiv
oseltamivir
result
reduct
median
durat
ill
incid
otiti
media
complic
influenza
vs
need
antibiot
prescript
influenza
vs
p
compar
placebo
common
sideeffect
vomit
systemat
review
metaanalys
publish
includ
studi
decemb
includ
two
studi
zanamivir
one
studi
oseltamivir
drug
administ
treatment
influenza
b
children
year
age
reduct
median
time
allevi
symptom
influenzaposit
children
compar
placebo
day
ci
zanamivir
day
oseltamivir
across
age
rel
reduct
complic
requir
antibiot
observ
zanamivir
children
specif
rel
reduct
observ
oseltamivir
updat
decemb
cochran
review
use
search
criteria
identifi
two
trial
oseltamivir
one
healthi
children
one
children
asthma
later
publish
one
zanamivir
conclus
therefor
respect
median
ill
durat
healthi
children
signific
reduct
complic
otiti
media
note
oseltamivir
trend
benefit
seen
zanamivir
vomit
significantli
common
among
oseltamivir
recipi
placebo
recipi
vs
review
note
may
differ
efficaci
accord
serotyp
oseltamivir
show
signific
reduct
time
resolut
influenza
b
respect
children
asthma
trend
reduct
time
freedom
ill
oseltamivir
recipi
reach
statist
signific
oseltamivir
appear
result
rapid
improv
pulmonari
function
well
toler
children
asthma
cochran
review
conclud
oseltamivir
prefer
drug
shown
benefit
regard
secondari
complic
also
conclud
evid
benefit
atrisk
children
ie
asthma
perspect
pandem
use
howev
note
evid
harm
group
regard
dose
oseltamivir
pharmacokinet
studi
suggest
young
children
clear
drug
faster
older
children
adolesc
adult
therefor
need
higher
dose
major
practic
issu
regard
zanamivir
mode
administr
limit
use
children
age
five
year
fda
guidanc
seven
year
age
develop
resist
oseltamivir
children
may
common
appreci
common
seen
adult
one
studi
resist
mutat
document
children
implic
widespread
use
pandem
situat
one
particular
issu
regard
paediatr
use
oseltamivir
appar
age
limit
licens
ie
children
one
year
age
particularli
import
epidem
year
children
influenza
children
six
month
age
like
hospitalis
basi
exclus
appear
rat
data
shown
high
mortal
infant
rat
seven
day
age
given
dose
mgkg
togeth
high
brain
level
oseltamivir
assum
reflect
immatur
blood
brain
barrier
age
reflect
product
literatur
fda
alert
although
publish
data
result
human
data
age
group
felt
would
difficult
monitor
cn
toxic
age
group
howev
fear
encephalopathi
due
influenza
young
children
japanes
paediatrician
use
antivir
hospitalis
children
part
clinic
manag
children
refer
hospit
pandem
flu
clinic
manag
patient
influenzalik
ill
influenza
pandem
use
infant
data
consecut
infant
japan
reveal
encephalopathi
mortal
recipi
second
japanes
report
children
one
year
treat
mgkgday
show
similar
efficaci
fever
group
older
children
seriou
advers
effect
data
effect
oseltamivir
given
two
day
onset
ill
like
less
effect
particular
littl
effect
five
six
day
ill
unless
child
immunosuppress
give
oseltamivir
sick
hospitalis
patient
theoret
like
decreas
infect
may
use
data
support
doubl
blind
placebo
control
studi
children
hospit
influenza
ill
hour
less
temperatur
randomis
receiv
either
ribavirin
placebo
sixtytwo
patient
placebo
group
ribavirin
group
confirm
diagnosi
influenza
time
reduct
temperatur
less
ribavirin
group
hour
compar
hour
placebo
group
p
differ
detect
group
publish
studi
year
sinc
report
thu
ribavirin
recommend
time
set
pandem
children
commun
consid
treatment
antivir
follow
acut
influenzalik
ill
fever
symptomat
two
day
less
oseltamivir
antivir
agent
choic
treatment
schedul
children
one
year
bodi
weight
kg
ie
year
mg
everi
h
bodi
weight
kg
ie
mg
everi
h
bodi
weight
kg
ie
year
mg
everi
h
children
sever
ill
hospit
oseltamivir
may
use
child
symptomat
less
six
day
oseltamivir
may
consid
treatment
infant
one
year
age
especi
sever
influenza
would
need
done
follow
appropri
discuss
parent
highlight
concern
anim
data
rel
pauciti
human
data
age
group
section
use
antibiot
hospitalis
children
get
antibiot
secondari
bacteri
infect
particularli
pneumonia
otiti
media
common
children
influenza
case
control
studi
outbreak
sever
pneumococc
pneumonia
demonstr
patient
sever
pneumonia
time
like
influenzalik
ill
four
time
like
posit
influenza
serolog
control
infect
staph
aureu
h
influenza
also
common
influenza
outbreak
random
control
trial
antibiot
children
age
four
month
year
present
influenzalik
symptom
influenza
epidem
show
decreas
incid
pneumonia
antibiotictr
group
vs
p
chang
durat
fever
incid
acut
otiti
media
interestingli
one
seven
case
pneumonia
placebo
group
thought
bacteri
author
postul
bacteri
proteas
facilit
propog
pathogenesi
influenza
mous
model
decreas
bacteri
number
henc
proteas
level
lung
may
decreas
viral
pneumonia
anoth
random
trial
cephalosporin
vs
macrolid
japanes
children
influenzalik
symptom
show
faster
allevi
fever
vs
day
p
macrolid
group
decreas
number
cxr
evid
pneumonia
vs
case
p
interstiti
chang
author
postul
antiinflammatori
effect
macrolid
may
respons
children
risk
complic
influenza
b
diseas
sever
enough
merit
hospit
admiss
influenza
pandem
treat
antibiot
provid
cover
pneumonia
staph
aureu
h
influenza
antibiot
choic
must
cover
like
pathogen
rare
blood
cultur
pleural
tap
provid
pathogen
antibiot
specif
tailor
eg
iv
benzylpenicillin
oral
amoxicillin
pneumonia
flucloxacillin
clindamycin
staph
aureu
part
clinic
manag
children
refer
hospit
use
antibiot
hospitalis
children
provision
guidelin
bisbtshpa
collabor
depart
health
version
octob
recent
random
control
trial
equival
oral
amoxicillin
vs
iv
benzylpenicillin
children
admit
hospit
communityacquir
pneumonia
show
differ
durat
ill
complic
oral
antibiot
given
provid
oral
fluid
toler
antibiot
choic
sever
complic
pneumonia
children
sever
ill
pneumonia
complic
influenza
second
agent
provid
good
cover
gram
posit
organ
ad
regim
eg
clarithromycin
cefuroxim
drug
given
intraven
ensur
high
serum
tissu
antibiot
level
section
acknowledg
committe
member
affili
chronic
obstruct
pulmonari
diseas
copd
includ
chronic
bronchiti
emphysema
condit
bronchiectasi
cystic
fibrosi
interstiti
lung
fibrosi
pneumoconiosi
bronchopulmonari
dysplasia
bpd
asthma
requir
continu
repeat
use
inhal
system
steroid
previou
exacerb
requir
hospit
admiss
children
previous
admit
hospit
lower
respiratori
tract
diseas
chronic
heart
diseas
congenit
heart
diseas
hypertens
cardiac
complic
chronic
heart
failur
individu
requir
regular
medic
andor
followup
ischaem
heart
diseas
chronic
renal
diseas
nephrot
syndrom
chronic
renal
failur
renal
transplant
chronic
liver
diseas
cirrhosi
inflammatori
bowel
diseas
diabet
chronic
metabol
disord
diabet
mellitu
requir
insulin
oral
hypoglycaem
drug
immunosuppress
malign
due
diseas
treatment
asplenia
splenic
dysfunct
hiv
infect
stage
malign
patient
undergo
chemotherapi
lead
immunosuppress
individu
like
system
steroid
month
dose
equival
prednisolon
mg
per
day
age
children
kg
dose
mg
per
kg
per
day
longstay
residenti
care
home
resid
includ
prison
young
offend
institut
univers
hall
resid
other
doctor
retain
discret
identifi
addit
individu
patient
recognis
high
risk
seriou
complic
develop
influenza
exampl
patient
haemoglobinopathi
neurolog
diseas
muscl
weak
cerebr
palsi
children
longterm
aspirin
increas
risk
rey
syndrom
highrisk
group
describ
appendix
larg
base
data
interpandem
influenza
cours
pandem
definit
highrisk
group
may
differ
detail
highrisk
patient
group
alter
accord
relev
clinicoepidemiolog
data
user
strongli
advis
refer
latest
version
guidelin
time
treat
sever
pneumonia
antibiot
indic
kg
mgkg
bd
